Most O
patients O
received O
radiotherapy O
in O
the O
adjuvant O
setting O
( O
52 O
of O
the O
83 O
) O
and O
had O
either O
an O
oral O
cavity O
( O
42 O
of O
the O
83 O
) O
or O
an O
oropharyngeal O
( O
16 O
of O
the O
83 O
) O
cancer O
. O

A O
lack O
of O
preliminary O
randomised O
data O
supporting O
the O
trial O
's O
hypotheses O
was O
thought O
to O
underlie O
the O
poor O
accrual O
, O
so O
, O
with O
no O
knowledge O
of O
the O
data O
, O
the O
independent O
trial O
steering O
committee O
agreed O
to O
the O
unusual O
step O
of O
releasing O
interim O
data O
. O

Pilates B-Claim
exercises I-Claim
are I-Claim
effective I-Claim
and I-Claim
safe I-Claim
in I-Claim
female I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

This O
study O
examined O
the O
characteristics O
of O
women O
enrolled O
in O
an O
intervention O
trial O
to O
treat O
sexual O
dysfunction O
, O
and O
explored O
the O
relationship O
between O
sexual O
functioning O
and O
psychological O
well-being O
. O

No B-Premise
difference I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
between I-Premise
topotecan I-Premise
and I-Premise
observation I-Premise
was I-Premise
observed I-Premise
at I-Premise
any I-Premise
assessment I-Premise
time I-Premise
or I-Premise
for I-Premise
any I-Premise
of I-Premise
the I-Premise
subscale I-Premise
scores I-Premise
. I-Premise

Primary O
endpoint O
was O
overall O
survival O
";" O
secondary O
endpoints O
were O
disease-free O
survival O
, O
response O
rate O
, O
toxicity O
, O
and O
quality O
of O
life O
. O

Nutritional O
intake O
( O
determined O
by O
diet O
history O
) O
and O
status O
( O
determined O
by O
Ottery O
's O
Subjective O
Global O
Assessment O
) O
, O
and O
QOL O
( O
determined O
by O
the O
European O
Organization O
for O
the O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
version O
3.0 O
[ O
EORTC O
QLQ-C30 O
] O
) O
were O
evaluated O
at O
baseline O
, O
at O
the O
end O
of O
RT O
, O
and O
at O
3 O
months O
. O

In B-Claim
patients I-Claim
with I-Claim
recurrent I-Claim
or I-Claim
metastatic I-Claim
SCCHN I-Claim
, I-Claim
while I-Claim
responses I-Claim
with I-Claim
gefitinib I-Claim
were I-Claim
seen I-Claim
, I-Claim
neither I-Claim
gefitinib I-Claim
250 I-Claim
nor I-Claim
500 I-Claim
mg/day I-Claim
improved I-Claim
overall I-Claim
survival I-Claim
compared I-Claim
with I-Claim
methotrexate I-Claim
. I-Claim

The B-Premise
overall I-Premise
response I-Premise
rates I-Premise
, I-Premise
which I-Premise
were I-Premise
confirmed I-Premise
by I-Premise
an I-Premise
independent I-Premise
expert I-Premise
panel I-Premise
, I-Premise
were I-Premise
13 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
3.4 I-Premise
% I-Premise
to I-Premise
23.3 I-Premise
% I-Premise
) I-Premise
, I-Premise
27 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
14.1 I-Premise
% I-Premise
to I-Premise
40.4 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
40 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
25.7 I-Premise
% I-Premise
to I-Premise
54.3 I-Premise
% I-Premise
) I-Premise
for I-Premise
arms I-Premise
A I-Premise
, I-Premise
B I-Premise
, I-Premise
and I-Premise
C I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Data O
were O
analysed O
up O
to O
6 O
months O
. O

Local B-Premise
recurrence I-Premise
rate I-Premise
and I-Premise
five-year I-Premise
survival I-Premise
were I-Premise
similar I-Premise
in I-Premise
both I-Premise
groups I-Premise
";" I-Premise
however B-Claim
, I-Claim
the I-Claim
limited I-Claim
number I-Claim
of I-Claim
patients I-Claim
does I-Claim
not I-Claim
allow I-Claim
firm I-Claim
conclusions I-Claim
. I-Claim

Total O
costs O
varied O
between O
treatment O
arms O
but O
these O
findings O
canceled O
out O
when O
SEMSs O
were O
compared O
with O
non-SEMS O
therapies O
( O
95 O
% O
CI O
-845.15-1,332.62 O
) O
. O

The B-Premise
occurrence I-Premise
of I-Premise
adverse I-Premise
reaction I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
was I-Premise
lower I-Premise
than I-Premise
that I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

The B-Premise
nutrition I-Premise
intervention I-Premise
group I-Premise
had I-Premise
a I-Premise
higher I-Premise
mean I-Premise
protein I-Premise
intake I-Premise
( I-Premise
1.1 I-Premise
to I-Premise
1.3 I-Premise
g/kg/day I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
standard I-Premise
practice I-Premise
group I-Premise
( I-Premise
1.0 I-Premise
to I-Premise
1.1 I-Premise
g/kg/day I-Premise
) I-Premise
( I-Premise
P=0.001 I-Premise
) I-Premise
. I-Premise

The O
potential O
long-term O
advantages O
of O
LRP O
over O
ORP O
remain O
to O
be O
determined O
. O

There B-Premise
was I-Premise
a I-Premise
trend I-Premise
towards I-Premise
an I-Premise
increase I-Premise
in I-Premise
OS I-Premise
, I-Premise
which I-Premise
reached I-Premise
statistical I-Premise
significance I-Premise
in I-Premise
the I-Premise
EGFR I-Premise
IHC-positive I-Premise
subgroup I-Premise
( I-Premise
p=0.0233 I-Premise
) I-Premise
. I-Premise

Survival O
was O
the O
primary O
end O
point O
with O
a O
33 O
% O
improvement O
relative O
to O
PC O
considered O
important O
( O
85 O
% O
power O
, O
alpha O
= O
5 O
% O
) O
. O

Thirty-six O
patients O
were O
treated O
. O

Outcomes B-Premise
in I-Premise
the I-Premise
nurse I-Premise
group I-Premise
were I-Premise
not I-Premise
inferior I-Premise
to I-Premise
outcomes I-Premise
in I-Premise
the I-Premise
gastroenterologist I-Premise
group I-Premise
( I-Premise
mean I-Premise
difference I-Premise
1·36 I-Premise
, I-Premise
one I-Premise
sided I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-1·48 I-Premise
) I-Premise
. I-Premise

Our B-Claim
study I-Claim
indicates I-Claim
that I-Claim
use I-Claim
of I-Claim
rhTSH I-Claim
preserves I-Claim
QoL I-Claim
in I-Claim
patients I-Claim
undergoing I-Claim
RI I-Claim
ablation I-Claim
and I-Claim
affords I-Claim
an I-Claim
ablation I-Claim
success I-Claim
rate I-Claim
comparable I-Claim
to I-Claim
that I-Claim
seen I-Claim
after I-Claim
thyroid I-Claim
hormone I-Claim
withdrawal I-Claim
. I-Claim

Histologically O
confirmed O
HIV-positive O
patients O
with O
Kaposi O
's O
sarcoma O
were O
randomized O
to O
receive O
supportive O
care O
only O
or O
supportive O
care O
plus O
either O
radiotherapy O
, O
oral O
Etoposide O
or O
a O
3-drug O
combination O
consisting O
of O
actinomycin-D O
, O
vincristine O
and O
bleomycin O
. O

Similarly B-Premise
, I-Premise
ASES I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
( I-Premise
p=0.001 I-Premise
) I-Premise
improved I-Premise
in I-Premise
both I-Premise
Group I-Premise
I I-Premise
and I-Premise
II I-Premise
without I-Premise
any I-Premise
significant I-Premise
difference I-Premise
between I-Premise
the I-Premise
groups I-Premise
. I-Premise

Patients O
were O
interviewed O
by O
telephone O
before O
treatment O
( O
baseline O
) O
, O
midtreatment O
, O
within O
1 O
month O
post-treatment O
, O
and O
at O
12 O
, O
18 O
, O
and O
24 O
months O
postbaseline O
by O
using O
questionnaires O
from O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ-C30 O
) O
, O
a O
breast O
systemic O
adverse O
effects O
scale O
( O
EORTC O
BR23 O
) O
, O
and O
the O
Hospital O
Anxiety O
and O
Depression O
Scale O
( O
HADS O
) O
. O

Further B-Claim
research I-Claim
is I-Claim
necessary I-Claim
to I-Claim
confirm I-Claim
this I-Claim
hypothesis I-Claim
in I-Claim
other I-Claim
samples I-Claim
, I-Claim
and I-Claim
causation I-Claim
can I-Claim
not I-Claim
be I-Claim
assumed I-Claim
based I-Claim
on I-Claim
this I-Claim
analysis I-Claim
. I-Claim

Analysis O
was O
performed O
after O
a O
29.2-month O
median O
follow-up O
( O
range O
, O
0 O
months O
to O
54.6 O
months O
) O
. O

By B-Claim
patient-reported I-Claim
questionnaire I-Claim
, I-Claim
78 I-Claim
Gy I-Claim
produced I-Claim
an I-Claim
increase I-Claim
in I-Claim
bowel I-Claim
movement I-Claim
frequency I-Claim
and I-Claim
no I-Claim
increase I-Claim
in I-Claim
bladder I-Claim
or I-Claim
sexual I-Claim
side I-Claim
effects I-Claim
at I-Claim
3 I-Claim
years I-Claim
compared I-Claim
with I-Claim
70 I-Claim
Gy I-Claim
. I-Claim

Measurements O
were O
performed O
before O
( O
T0 O
) O
and O
after O
the O
rehabilitation O
program O
( O
T1 O
) O
, O
and O
at O
a O
3-month O
follow-up O
( O
T2 O
) O
. O

We O
compared O
efficacy O
of O
gefitinib O
with O
gemcitabine O
and O
cisplatin O
( O
GP O
) O
chemotherapy O
in O
this O
group O
of O
patients O
as O
first-line O
therapy O
. O

Of O
260 O
eligible O
patients O
, O
104 O
( O
40 O
% O
) O
agreed O
to O
participate O
, O
and O
93 O
were O
randomised O
. O

We O
conducted O
a O
pragmatic O
, O
randomized O
controlled O
trial O
comparing O
acupuncture O
with O
enhanced O
usual O
care O
. O

A O
cycle O
of O
BEP O
consisted O
of O
etoposide O
500 O
mg/m O
( O
2 O
) O
, O
administered O
at O
either O
100 O
mg/m O
( O
2 O
) O
days O
1 O
through O
5 O
or O
165 O
mg/m O
( O
2 O
) O
days O
1 O
through O
3 O
, O
cisplatin O
100 O
mg/m O
( O
2 O
) O
, O
administered O
at O
either O
20 O
mg/m O
( O
2 O
) O
days O
1 O
through O
5 O
or O
50 O
mg/m O
( O
2 O
) O
days O
1 O
and O
2 O
. O

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
interaction I-Premise
between I-Premise
gender I-Premise
and I-Premise
KPS I-Premise
using I-Premise
FLIC I-Premise
( I-Premise
P I-Premise
= I-Premise
0.009 I-Premise
) I-Premise
, I-Premise
which I-Premise
also I-Premise
showed I-Premise
a I-Premise
trend I-Premise
toward I-Premise
significance I-Premise
with I-Premise
FACT I-Premise
( I-Premise
P I-Premise
= I-Premise
0.09 I-Premise
) I-Premise
. I-Premise

Of O
289 O
patients O
screened O
, O
243 O
were O
randomly O
assigned O
and O
164 O
( O
CE O
, O
66 O
of O
95 O
patients O
";" O
THC O
, O
65 O
of O
100 O
patients O
";" O
and O
PL O
, O
33 O
of O
48 O
patients O
) O
completed O
treatment O
. O

Among B-Premise
patients I-Premise
who I-Premise
had I-Premise
measurable I-Premise
disease I-Premise
( I-Premise
TC I-Premise
, I-Premise
n I-Premise
= I-Premise
147 I-Premise
";" I-Premise
TC-Top I-Premise
, I-Premise
n I-Premise
= I-Premise
145 I-Premise
) I-Premise
, I-Premise
overall I-Premise
( I-Premise
i.e. I-Premise
, I-Premise
complete I-Premise
or I-Premise
partial I-Premise
) I-Premise
response I-Premise
was I-Premise
69.0 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
61.4 I-Premise
% I-Premise
to I-Premise
76.5 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
TC-Top I-Premise
arm I-Premise
and I-Premise
76.2 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
69.3 I-Premise
% I-Premise
to I-Premise
83.1 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
TC I-Premise
arm I-Premise
( I-Premise
P I-Premise
= I-Premise
.166 I-Premise
) I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
was I-Premise
7.8 I-Premise
months I-Premise
( I-Premise
range I-Premise
, I-Premise
4-11.6 I-Premise
months I-Premise
) I-Premise
. I-Premise

The B-Premise
incidence I-Premise
of I-Premise
lymphedema I-Premise
during I-Premise
the I-Premise
study I-Premise
was I-Premise
low I-Premise
for I-Premise
both I-Premise
groups I-Premise
and I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
groups I-Premise
. I-Premise

The B-Premise
venlafaxine I-Premise
group I-Premise
experienced I-Premise
18 I-Premise
incidences I-Premise
of I-Premise
adverse I-Premise
effects I-Premise
( I-Premise
eg I-Premise
, I-Premise
nausea I-Premise
, I-Premise
dry I-Premise
mouth I-Premise
, I-Premise
dizziness I-Premise
, I-Premise
anxiety I-Premise
) I-Premise
, I-Premise
whereas I-Premise
the I-Premise
acupuncture I-Premise
group I-Premise
experienced I-Premise
no I-Premise
negative I-Premise
adverse I-Premise
effects I-Premise
. I-Premise

Indeed O
, O
four B-Premise
cases I-Premise
of I-Premise
postoperative I-Premise
infectious I-Premise
complications I-Premise
were I-Premise
noted I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
but I-Premise
no I-Premise
postoperative I-Premise
infectious I-Premise
complications I-Premise
were I-Premise
observed I-Premise
in I-Premise
the I-Premise
interventional I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.037 I-Premise
) I-Premise
. I-Premise

The B-Premise
5-year I-Premise
biochemical I-Premise
+/- I-Premise
clinical I-Premise
relapse-free I-Premise
and I-Premise
overall I-Premise
survival I-Premise
was I-Premise
55.9 I-Premise
% I-Premise
and I-Premise
85.3 I-Premise
% I-Premise
respectively I-Premise
for I-Premise
all I-Premise
patients I-Premise
, I-Premise
and I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
the I-Premise
two I-Premise
schedules I-Premise
. I-Premise

RTOG O
89-01 O
accrued O
75 O
patients O
, O
of O
whom O
73 O
were O
eligible O
and O
analyzable O
. O

Only B-Claim
the I-Claim
combined I-Claim
intervention I-Claim
yielded I-Claim
effects I-Claim
on I-Claim
quality I-Claim
of I-Claim
life I-Claim
outcomes I-Claim
, I-Claim
and I-Claim
these I-Claim
were I-Claim
limited I-Claim
to I-Claim
anxiety I-Claim
and I-Claim
depression I-Claim
. I-Claim

Results B-Premise
from I-Premise
the I-Premise
non-randomised I-Premise
patients I-Premise
did I-Premise
not I-Premise
confirm I-Premise
this I-Premise
effect I-Premise
, I-Premise
however I-Premise
. I-Premise

The B-Premise
overall I-Premise
QoL-scale I-Premise
QLQ-C30-HRQoL I-Premise
showed I-Premise
a I-Premise
significant I-Premise
time I-Premise
trend I-Premise
towards I-Premise
more I-Premise
favourable I-Premise
mean I-Premise
values I-Premise
during I-Premise
protocol I-Premise
treatment I-Premise
without I-Premise
differences I-Premise
between I-Premise
MP I-Premise
and I-Premise
MPT I-Premise
. I-Premise

Two O
participants O
in O
the O
III O
+ O
ISG O
dropped O
out O
, O
compared O
with O
five O
in O
III O
( O
p O
= O
0.39 O
) O
. O

The B-Premise
median I-Premise
TDD I-Premise
in I-Premise
HRQOL I-Premise
was I-Premise
8.3 I-Premise
months I-Premise
with I-Premise
EVE I-Premise
+ I-Premise
EXE I-Premise
versus I-Premise
5.8 I-Premise
months I-Premise
with I-Premise
PBO I-Premise
+ I-Premise
EXE I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.74 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.0084 I-Premise
) I-Premise
. I-Premise

However O
, O
loss O
of O
power O
was O
not O
an O
issue O
because O
of O
the O
planned O
large O
target O
sample O
size O
. O

Larger B-Claim
studies I-Claim
are I-Claim
required I-Claim
to I-Claim
validate I-Claim
these I-Claim
results I-Claim
. I-Claim

Aqua O
lymphatic O
therapy O
( O
ALT O
) O
is O
a O
novel O
treatment O
for O
limb O
volume O
reduction O
. O

Asymptomatic B-Premise
Corrected I-Premise
QT I-Premise
interval I-Premise
( I-Premise
QTC I-Premise
) I-Premise
prolongation I-Premise
was I-Premise
observed I-Premise
in I-Premise
eight I-Premise
vandetanib I-Premise
patients I-Premise
. I-Premise

SNBM B-Claim
was I-Claim
successfully I-Claim
undertaken I-Claim
in I-Claim
a I-Claim
wide I-Claim
range I-Claim
of I-Claim
surgical I-Claim
centers I-Claim
and I-Claim
caused I-Claim
significantly I-Claim
less I-Claim
morbidity I-Claim
than I-Claim
RAC I-Claim
. I-Claim

Treatment O
arms O
were O
compared O
using O
differences O
of O
least O
squares O
mean O
( O
LSM O
) O
changes O
from O
baseline O
and O
95 O
% O
confidence O
intervals O
( O
CIs O
) O
at O
each O
timepoint O
and O
overall O
. O

Combined B-Claim
with I-Claim
QOL I-Claim
results I-Claim
, I-Claim
the I-Claim
significant I-Claim
increase I-Claim
in I-Claim
response I-Claim
and I-Claim
PFS I-Claim
in I-Claim
the I-Claim
CP I-Claim
arm I-Claim
and I-Claim
the I-Claim
higher I-Claim
drop-out I-Claim
rate I-Claim
in I-Claim
the I-Claim
C I-Claim
arm I-Claim
suggest I-Claim
a I-Claim
better I-Claim
outcome I-Claim
for I-Claim
the I-Claim
combination I-Claim
regimen I-Claim
despite I-Claim
its I-Claim
increased I-Claim
myelosuppression I-Claim
. I-Claim

The O
trial O
was O
prematurely O
closed O
during O
recruitment O
, O
after O
a O
median O
follow-up O
of O
11.9 O
months O
( O
interquartile O
range O
7.1-19.6 O
, O
total O
6498 O
women O
years O
) O
in O
those O
enrolled O
, O
after O
the O
publication O
of O
early O
results O
from O
the O
women O
's O
health O
initiative O
study O
. O

This O
study O
examined O
( O
i O
) O
whether O
patient-caregiver O
dyads O
( O
i.e. O
, O
pairs O
) O
randomly O
assigned O
to O
a O
brief O
or O
extensive O
dyadic O
intervention O
( O
the O
FOCUS O
Program O
) O
had O
better O
outcomes O
than O
dyads O
randomly O
assigned O
to O
usual O
care O
and O
( O
ii O
) O
whether O
patients O
' O
risk O
for O
distress O
and O
other O
factors O
moderated O
the O
effect O
of O
the O
brief O
or O
extensive O
program O
on O
outcomes O
. O

In O
a O
prospective O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
, O
407 O
melanoma O
patients O
in O
stage O
IIA O
( O
301 O
patients O
) O
and O
IIB O
( O
106 O
patients O
) O
were O
randomly O
assigned O
to O
either O
IFNalpha O
and O
isotretinoin O
( O
isotretinoin O
group O
";" O
206 O
patients O
) O
or O
IFNalpha O
and O
placebo O
( O
placebo O
group O
";" O
201 O
patients O
) O
after O
excision O
of O
the O
primary O
tumor O
. O

No B-Premise
liver I-Premise
cancers I-Premise
or I-Premise
increase I-Premise
in I-Premise
colon I-Premise
, I-Premise
rectal I-Premise
, I-Premise
ovarian I-Premise
, I-Premise
or I-Premise
other I-Premise
tumors I-Premise
was I-Premise
observed I-Premise
in I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
. I-Premise

In O
both O
arms O
, O
radiotherapy O
was O
delivered O
as O
60 O
Gy/30 O
fractions O
to O
the O
tumor O
site O
with O
a O
2 O
to O
3 O
cm O
margin O
. O

For O
each O
outcome O
measure O
, O
a O
repeated-measures O
analysis O
of O
variance O
model O
, O
which O
incorporated O
week O
0 O
measurements O
as O
a O
covariate O
, O
was O
used O
to O
compare O
treatment O
groups O
at O
8 O
and O
12 O
weeks O
. O

We O
report O
on O
the O
quality O
of O
life O
( O
QOL O
) O
outcomes O
for O
this O
trial O
. O

To O
carry O
out O
a O
preliminary O
trial O
evaluating O
the O
effectiveness O
of O
two O
types O
of O
homeopathy O
for O
the O
treatment O
of O
menopausal O
symptoms O
in O
breast O
cancer O
survivors O
. O

In O
one O
of O
these O
trials O
, O
HOVON49 O
, O
a O
prospective O
health-related O
quality-of-life O
( O
HRQoL O
) O
study O
was O
initiated O
in O
order O
to O
assess O
the O
impact O
of O
thalidomide O
on O
QoL O
. O

A O
total O
of O
402 O
eligible O
patients O
were O
registered O
to O
step O
1 O
, O
and O
223 O
eligible O
patients O
were O
registered O
to O
step O
2 O
( O
observation O
, O
n O
= O
111 O
";" O
topotecan O
, O
n O
= O
112 O
) O
. O

Breast B-Premise
symptoms I-Premise
increased I-Premise
for I-Premise
both I-Premise
groups I-Premise
during I-Premise
radiotherapy I-Premise
, I-Premise
without I-Premise
loss I-Premise
of I-Premise
strength I-Premise
or I-Premise
range I-Premise
of I-Premise
movement I-Premise
. I-Premise

Efficacy O
was O
assessed O
after O
the O
completion O
of O
3 O
treatment O
cycles O
";" O
28.9 O
% O
of O
patients O
( O
22 O
of O
76 O
patients O
) O
responded O
( O
no O
CRs O
, O
1 O
PR O
, O
and O
21 O
SDs O
) O
. O

QoL O
was O
assessed O
in O
350 O
patients O
randomly O
assigned O
to O
either O
standard O
chemotherapy O
( O
cyclophosphamide O
, O
methotrexate O
, O
and O
fluorouracil O
[ O
CMF O
] O
or O
doxorubicin O
and O
cyclophosphamide O
[ O
AC O
] O
";" O
n O
= O
182 O
) O
or O
capecitabine O
( O
n O
= O
168 O
) O
. O

To O
study O
the O
effects O
of O
Fuzheng O
Jianpi O
Decoction O
( O
FJD O
) O
combined O
chemotherapy O
on O
the O
quality O
of O
life O
( O
QOL O
) O
and O
the O
survival O
time O
of O
children O
with O
solid O
tumor O
. O

Patients O
performed O
5 O
targeted O
swallowing O
exercises O
throughout O
their O
CRT O
and O
participated O
in O
weekly O
swallowing O
therapy O
sessions O
to O
promote O
adherence O
and O
accurate O
technique O
. O

Baseline O
HRQOL O
scores O
did O
not O
differ O
between O
groups O
. O

All O
statistical O
tests O
were O
two-sided O
. O

The O
purpose O
of O
our O
study O
was O
to O
evaluate O
the O
effect O
of O
cognitive O
behavioral O
therapy O
( O
CBT O
) O
, O
physical O
exercise O
( O
PE O
) O
, O
and O
of O
these O
two O
interventions O
combined O
( O
CBT/PE O
) O
on O
menopausal O
symptoms O
( O
primary O
outcome O
) O
, O
body O
image O
, O
sexual O
functioning O
, O
psychological O
well-being O
, O
and O
health-related O
quality O
of O
life O
( O
secondary O
outcomes O
) O
in O
patients O
with O
breast O
cancer O
experiencing O
treatment-induced O
menopause O
. O

As O
treatment O
for O
mNSCLC O
is O
non-curative O
, O
its O
impact O
on O
patient O
health-related O
quality O
of O
life O
( O
HRQoL O
) O
is O
an O
important O
consideration O
. O

To O
compare O
directly O
the O
effect O
of O
intensity-modulated O
radiotherapy O
( O
IMRT O
) O
vs. O
conventional O
radiotherapy O
( O
CRT O
) O
on O
salivary O
flow O
and O
quality O
of O
life O
( O
QoL O
) O
in O
patients O
with O
early-stage O
nasopharyngeal O
carcinoma O
( O
NPC O
) O
. O

In B-Premise
grade I-Premise
IV I-Premise
the I-Premise
corresponding I-Premise
median I-Premise
survival I-Premise
time I-Premise
was I-Premise
12.3 I-Premise
( I-Premise
2.1-89.2 I-Premise
) I-Premise
and I-Premise
10.3 I-Premise
( I-Premise
0.3-91.7+ I-Premise
) I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Estramustine O
was O
given O
orally O
, O
280 O
mg O
twice O
daily O
, O
as O
soon O
as O
the O
diagnosis O
was O
established O
, O
during O
and O
after O
the O
radiotherapy O
for O
a O
period O
of O
in O
total O
3 O
months O
. O

The O
primary O
hypothesis O
was O
that O
duloxetine O
would O
be O
more O
effective O
than O
placebo O
in O
decreasing O
chemotherapy-induced O
peripheral O
neuropathic O
pain O
. O

A O
multicenter O
, O
double-blind O
, O
randomized O
clinical O
trial O
was O
performed O
to O
test O
if O
breast O
IMRT O
would O
reduce O
the O
rate O
of O
acute O
skin O
reaction O
( O
notably O
moist O
desquamation O
) O
, O
decrease O
pain O
, O
and O
improve O
quality O
of O
life O
compared O
with O
standard O
radiotherapy O
using O
wedges O
. O

At B-Premise
6 I-Premise
months I-Premise
, I-Premise
there I-Premise
was I-Premise
a I-Premise
clinically I-Premise
relevant I-Premise
, I-Premise
but I-Premise
nonsignificant I-Premise
reduction I-Premise
in I-Premise
presentations I-Premise
to I-Premise
emergency I-Premise
departments I-Premise
( I-Premise
21 I-Premise
% I-Premise
vs I-Premise
33 I-Premise
% I-Premise
";" I-Premise
χ1 I-Premise
= I-Premise
1.41 I-Premise
, I-Premise
P I-Premise
= I-Premise
.23 I-Premise
) I-Premise
and I-Premise
readmission I-Premise
to I-Premise
the I-Premise
hospital I-Premise
( I-Premise
37 I-Premise
% I-Premise
vs I-Premise
47 I-Premise
% I-Premise
";" I-Premise
χ1 I-Premise
= I-Premise
0.82 I-Premise
, I-Premise
P I-Premise
= I-Premise
.37 I-Premise
) I-Premise
among I-Premise
intervention I-Premise
compared I-Premise
with I-Premise
control I-Premise
group I-Premise
participants I-Premise
. I-Premise

The O
study O
included O
the O
assessment O
of O
patient O
quality O
of O
life O
. O

HDC B-Claim
has I-Claim
a I-Claim
negative I-Claim
impact I-Claim
on I-Claim
QOL I-Claim
even I-Claim
after I-Claim
treatment I-Claim
phase I-Claim
. I-Claim

Research B-Claim
is I-Claim
needed I-Claim
to I-Claim
assess I-Claim
the I-Claim
long I-Claim
term I-Claim
risks I-Claim
and I-Claim
benefits I-Claim
of I-Claim
starting I-Claim
hormone I-Claim
replacement I-Claim
therapy I-Claim
near I-Claim
the I-Claim
menopause I-Claim
, I-Claim
when I-Claim
the I-Claim
effect I-Claim
may I-Claim
be I-Claim
different I-Claim
. I-Claim

Secondary O
outcomes O
were O
other O
domains O
of O
the O
SCNS O
, O
psychological O
status O
, O
continuity O
of O
care O
, O
quality O
of O
life O
, O
and O
resource O
use O
. O

The B-Premise
estimated I-Premise
4-year I-Premise
survival I-Premise
rate I-Premise
was I-Premise
78.1 I-Premise
% I-Premise
with I-Premise
the I-Premise
16-week I-Premise
regimen I-Premise
versus I-Premise
71.4 I-Premise
% I-Premise
with I-Premise
CAF I-Premise
( I-Premise
P I-Premise
= I-Premise
.10 I-Premise
, I-Premise
two-sided I-Premise
";" I-Premise
P I-Premise
= I-Premise
.05 I-Premise
, I-Premise
one-sided I-Premise
) I-Premise
. I-Premise

The O
aim O
of O
this O
randomised O
study O
was O
to O
evaluate O
the O
longitudinal O
changes O
in O
body O
composition O
and O
lipid O
profiles O
in O
postmenopausal O
women O
switched O
from O
tamoxifen O
to O
exemestane O
. O

This O
study O
examined O
whether O
changes O
in O
self-efficacy O
explain O
the O
effects O
of O
a O
mailed O
print O
intervention O
on O
long-term O
dietary O
practices O
of O
breast O
and O
prostate O
cancer O
survivors O
. O

Fatigue O
dimensions O
, O
fatigue O
NRS O
score O
, O
interference O
of O
fatigue O
with O
daily O
life O
, O
symptom O
burden O
, O
quality O
of O
life O
, O
anxiety O
, O
and O
depression O
were O
measured O
at O
baseline O
and O
after O
1 O
, O
2 O
, O
and O
3 O
months O
. O

Arm O
circumferences O
were O
measured O
before O
and O
the O
1st O
, O
3rd O
, O
and O
6th O
weeks O
of O
the O
treatment O
. O

Improvements B-Claim
were I-Claim
seen I-Claim
for I-Claim
symptom I-Claim
scores I-Claim
over I-Claim
the I-Claim
study I-Claim
period I-Claim
. I-Claim

At B-Premise
12 I-Premise
months I-Premise
, I-Premise
63 I-Premise
% I-Premise
of I-Premise
intervention I-Premise
patients I-Premise
had I-Premise
a I-Premise
50 I-Premise
% I-Premise
or I-Premise
greater I-Premise
reduction I-Premise
in I-Premise
depressive I-Premise
symptoms I-Premise
from I-Premise
baseline I-Premise
as I-Premise
assessed I-Premise
by I-Premise
the I-Premise
Patient I-Premise
Health I-Premise
Questionnaire-9 I-Premise
( I-Premise
PHQ-9 I-Premise
) I-Premise
depression I-Premise
scale I-Premise
compared I-Premise
with I-Premise
50 I-Premise
% I-Premise
of I-Premise
EUC I-Premise
patients I-Premise
( I-Premise
odds I-Premise
ratio I-Premise
[ I-Premise
OR I-Premise
] I-Premise
= I-Premise
1.98 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.16 I-Premise
to I-Premise
3.38 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
. I-Premise

Effects O
varied O
by O
intervention O
dose O
. O

Hot B-Claim
flash I-Claim
frequency I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
was I-Claim
reduced I-Claim
following I-Claim
acupuncture I-Claim
. I-Claim

A O
prospective O
randomized O
study O
was O
conducted O
from O
January O
2003 O
. O

Drug O
toxicity O
and O
quality O
of O
life O
were O
observed O
. O

The O
consumption O
of O
non-protein O
calories O
did O
not O
differ O
significantly O
between O
the O
two O
patient O
groups O
. O

Their O
anthropometric O
data O
, O
body O
composition O
, O
including O
fat O
mass O
( O
FM O
) O
and O
fat-free O
mass O
( O
FFM O
) O
, O
and O
lipid O
profiles O
, O
caloric O
intake O
and O
physical O
activity O
were O
assessed O
1 O
week O
before O
randomisation O
, O
and O
6 O
and O
12 O
months O
later O
. O

To O
compare O
short- O
and O
long-term O
effects O
of O
adjuvant O
treatment O
versus O
observation O
after O
surgery O
on O
health-related O
quality O
of O
life O
( O
HRQL O
) O
of O
prostate O
cancer O
patients O
. O

Symptoms O
were O
analyzed O
by O
repeated-measures O
analysis O
of O
variance O
. O

Forty O
were O
not O
eligible O
for O
randomization O
, O
and O
58 O
patients O
were O
randomly O
assigned O
, O
32 O
and O
26 O
patients O
in O
the O
INT O
and O
CONT O
arms O
, O
respectively O
. O

The O
purpose O
of O
this O
blinded O
, O
randomized O
clinical O
trial O
was O
to O
compare O
two O
topical O
agents O
( O
Calendula O
Weleda O
cream O
vs. O
Essex O
cream O
) O
in O
reducing O
the O
risk O
of O
severe O
acute O
radiation O
skin O
reactions O
( O
ARSR O
) O
in O
relation O
to O
adjuvant O
radiotherapy O
( O
RT O
) O
for O
breast O
cancer O
. O

Primary O
outcome O
was O
physical O
function O
after O
12 O
months O
estimated O
by O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
QLQ-C30 O
questionnaire O
( O
scale O
0-100 O
) O
. O

Three-month B-Premise
survival I-Premise
rates I-Premise
for I-Premise
the I-Premise
P I-Premise
, I-Premise
TMX60 I-Premise
, I-Premise
and I-Premise
TMX120 I-Premise
groups I-Premise
were I-Premise
44 I-Premise
% I-Premise
, I-Premise
41 I-Premise
% I-Premise
, I-Premise
and I-Premise
35 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
, I-Premise
with I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
trend I-Premise
difference I-Premise
in I-Premise
survival I-Premise
across I-Premise
the I-Premise
3 I-Premise
treatment I-Premise
regimens I-Premise
( I-Premise
P I-Premise
=.011 I-Premise
) I-Premise
. I-Premise

The B-Premise
primary I-Premise
outcome I-Premise
measure I-Premise
was I-Premise
achieved I-Premise
in I-Premise
28 I-Premise
% I-Premise
of I-Premise
the I-Premise
immediate I-Premise
treatment I-Premise
group I-Premise
and I-Premise
26 I-Premise
% I-Premise
of I-Premise
patients I-Premise
from I-Premise
the I-Premise
delayed I-Premise
treatment I-Premise
group I-Premise
( I-Premise
27/97 I-Premise
and I-Premise
27/103 I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
absolute I-Premise
difference I-Premise
1.6 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
-10.7 I-Premise
% I-Premise
to I-Premise
13.9 I-Premise
% I-Premise
) I-Premise
. I-Premise

Twenty-six O
patients O
with O
head O
and O
neck O
cancer O
receiving O
CRT O
. O

However B-Claim
, I-Claim
it I-Claim
is I-Claim
not I-Claim
clear I-Claim
whether I-Claim
psychological I-Claim
improvements I-Claim
are I-Claim
, I-Claim
in I-Claim
turn I-Claim
, I-Claim
related I-Claim
to I-Claim
improved I-Claim
health I-Claim
. I-Claim

N O
, O
N-diethyl-2- O
[ O
-4 O
( O
phenylmethyl O
) O
phenoxy O
] O
ethanamine O
( O
DPPE O
";" O
tesmilifene O
) O
is O
a O
novel O
agent O
that O
augments O
chemotherapy O
cytotoxicity O
in O
vitro O
and O
in O
vivo O
. O

Local O
symptoms O
were O
scored O
on O
a O
physician-assessed O
, O
five-point O
categorical O
scale O
and O
summed O
to O
produce O
a O
total O
symptom O
score O
( O
TSS O
) O
. O

The B-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
for I-Premise
marimastat I-Premise
patients I-Premise
was I-Premise
4.3 I-Premise
months I-Premise
compared I-Premise
with I-Premise
4.4 I-Premise
months I-Premise
for I-Premise
placebo I-Premise
patients I-Premise
( I-Premise
P I-Premise
=.81 I-Premise
) I-Premise
. I-Premise

Cancer O
cachexia O
is O
a O
common O
problem O
among O
advanced O
cancer O
patients O
. O

Pretreatment B-Premise
serum I-Premise
erythropoietin I-Premise
levels I-Premise
were I-Premise
lower I-Premise
in I-Premise
responders I-Premise
than I-Premise
in I-Premise
nonresponders I-Premise
( I-Premise
73.5 I-Premise
IU/L I-Premise
and I-Premise
86.3 I-Premise
IU/L I-Premise
means I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Data O
on O
survival O
time O
and O
medical O
care O
resource O
use O
were O
prospectively O
collected O
in O
the O
trial O
. O

Chemotherapy O
regimens O
consisted O
of O
a O
control O
FU O
arm O
( O
5-FU O
500 O
mg/m O
( O
2 O
) O
/day O
for O
5 O
days O
) O
and O
the O
investigational O
FUP O
arm O
( O
continuous O
5-FU O
1000 O
mg/m O
( O
2 O
) O
/day O
for O
5 O
days O
plus O
cisplatin O
100 O
mg/m O
( O
2 O
) O
on O
day O
1 O
or O
day O
2 O
) O
. O

Climacteric B-Premise
symptoms I-Premise
remained I-Premise
significantly I-Premise
below I-Premise
baseline I-Premise
values I-Premise
after I-Premise
dosage I-Premise
reduction I-Premise
";" I-Premise
some B-Premise
symptoms I-Premise
recurred I-Premise
after I-Premise
discontinuation I-Premise
of I-Premise
ccHRT I-Premise
. I-Premise

One O
hundred O
and O
twenty-one O
patients O
were O
enrolled O
through O
ten O
Cancer O
and O
Leukemia O
Group O
B O
( O
CALGB O
) O
institutions O
";" O
100 O
patients O
had O
breast O
cancer O
and O
21 O
had O
colorectal O
cancer O
. O

Patients O
( O
aged O
≥18 O
years O
) O
with O
a O
terminal O
prognosis O
( O
life O
expectancy O
≤6 O
months O
) O
who O
were O
receiving O
palliative O
care O
in O
a O
hospital O
or O
community O
setting O
( O
hospice O
or O
home O
) O
in O
Canada O
, O
USA O
, O
and O
Australia O
were O
randomly O
assigned O
to O
dignity O
therapy O
, O
client-centred O
care O
, O
or O
standard O
palliative O
care O
in O
a O
1:1:1 O
ratio O
. O

To O
determine O
whether O
a O
new O
agent O
, O
paclitaxel O
, O
would O
further O
improve O
survival O
in O
NSCLC O
, O
the O
Eastern O
Cooperative O
Oncology O
Group O
conducted O
a O
randomized O
trial O
comparing O
paclitaxel O
plus O
cisplatin O
to O
a O
standard O
chemotherapy O
regimen O
consisting O
of O
cisplatin O
and O
etoposide O
. O

For O
this O
clinical O
trial O
, O
263 O
patient-spouse O
dyads O
were O
stratified O
by O
research O
site O
, O
phase O
of O
illness O
, O
and O
treatment O
";" O
then O
, O
they O
were O
randomized O
to O
the O
control O
group O
( O
standard O
care O
) O
or O
the O
experimental O
group O
( O
standard O
care O
plus O
a O
5-session O
family O
intervention O
) O
. O

Axillary B-Claim
clearance I-Claim
in I-Claim
early I-Claim
breast I-Claim
cancer I-Claim
aims I-Claim
to I-Claim
improve I-Claim
locoregional I-Claim
control I-Claim
and I-Claim
provide I-Claim
staging I-Claim
information I-Claim
but O
is O
associated O
with O
undesirable O
morbidity O
. O

Analyses O
were O
performed O
on O
an O
intention-to-treat O
basis O
. O

Using O
the O
Phoenix O
definition O
, O
the O
5-year O
biochemical O
relapse O
rate O
was O
32 O
% O
and O
23.5 O
% O
, O
respectively O
( O
p O
= O
.09 O
) O
. O

In O
this O
study O
, O
the O
authors O
examined O
personal O
and O
clinical O
factors O
that O
may O
predict O
exercise O
training O
responses O
. O

Patients O
and O
clinical O
sites O
were O
informed O
of O
allocation O
to O
early O
treatment O
, O
and O
treatment O
was O
started O
as O
soon O
as O
possible O
within O
28 O
days O
of O
the O
increased O
CA125 O
measurement O
. O

One O
hundred O
and O
eight O
cancer O
patients O
, O
no O
longer O
responsive O
to O
opioids O
for O
moderate O
pain O
, O
were O
selected O
to O
randomly O
receive O
initial O
daily O
doses O
of O
60 O
mg O
of O
oral O
sustained-release O
morphine O
, O
15 O
mg O
of O
oral O
methadone O
, O
or O
0.6 O
mg O
( O
25 O
microg/h O
) O
of O
transdermal O
fentanyl O
. O

The O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
impact O
of O
pilates O
exercises O
on O
physical O
performance O
, O
flexibility O
, O
fatigue O
, O
depression O
and O
quality O
of O
life O
in O
women O
who O
had O
been O
treated O
for O
breast O
cancer O
. O

One O
hundred O
two O
patients O
with O
resected O
PPC O
consented O
to O
participate O
in O
this O
study O
and O
were O
randomized O
to O
either O
an O
intervention O
group O
( O
IG O
) O
or O
a O
usual O
care O
group O
( O
UCG O
) O
. O

Dysuria O
was O
evaluated O
on O
a O
0-10 O
scale O
, O
before O
brachytherapy O
and O
then O
at O
1 O
, O
3 O
, O
6 O
and O
12 O
months O
afterward O
, O
with O
a O
median O
of O
four O
dysuria O
questionnaires O
per O
patient O
. O

The O
FDA O
reviewed O
raw O
data O
in O
electronic O
format O
from O
a O
randomized O
controlled O
clinical O
trial O
comparing O
erlotinib O
with O
placebo O
in O
patients O
with O
locally O
advanced O
or O
metastatic O
NSCLC O
after O
failure O
of O
at O
least O
one O
prior O
chemotherapy O
regimen O
. O

Gemcitabine O
for O
advanced O
pancreatic O
cancer O
( O
APC O
) O
is O
palliative O
and O
the O
prognosis O
is O
poor O
, O
making O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
particularly O
important O
. O

Intensity O
of O
service O
did O
not O
differ O
between O
the O
2 O
groups O
. O

No O
prospective O
comparison O
with O
nitrosourea-based O
chemotherapy O
exists O
. O

To O
assess O
the O
efficacy O
of O
monthly O
degarelix O
treatment O
for O
reduction O
of O
total O
prostate O
volume O
( O
TPV O
) O
, O
relief O
of O
lower O
urinary O
tract O
symptoms O
( O
LUTS O
) O
and O
improvement O
of O
quality O
of O
life O
( O
QoL O
) O
in O
patients O
with O
prostate O
cancer O
( O
PCa O
) O
using O
monthly O
goserelin O
as O
active O
control O
. O

A O
randomized O
controlled O
trial O
previously O
conducted O
in O
radiation O
oncology O
patients O
demonstrated O
that O
nutrition O
intervention O
had O
a O
beneficial O
impact O
on O
body O
weight O
, O
nutritional O
status O
, O
and O
quality O
of O
life O
compared O
with O
standard O
practice O
, O
but O
it O
did O
not O
report O
on O
dietary O
intake O
data O
. O

In B-Premise
70 I-Premise
evaluable I-Premise
study I-Premise
subjects I-Premise
, I-Premise
the I-Premise
curative I-Premise
efficacy I-Premise
in I-Premise
the I-Premise
bevacizumab I-Premise
group I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
than I-Premise
that I-Premise
found I-Premise
in I-Premise
the I-Premise
cisplatin I-Premise
group I-Premise
( I-Premise
83.33 I-Premise
vs. I-Premise
50.00 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Clinically B-Premise
relevant I-Premise
improvements I-Premise
in I-Premise
symptoms I-Premise
and I-Premise
mood I-Premise
disturbance I-Premise
were I-Premise
seen I-Premise
for I-Premise
both I-Premise
groups I-Premise
over I-Premise
the I-Premise
study I-Premise
period I-Premise
. I-Premise

Fatigue B-Premise
scores I-Premise
indicated I-Premise
less I-Premise
increase I-Premise
and I-Premise
physical I-Premise
well-being I-Premise
subscale I-Premise
scores I-Premise
showed I-Premise
less I-Premise
decline I-Premise
for I-Premise
the I-Premise
experimental I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0.008 I-Premise
and I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Analysis O
was O
by O
intention O
to O
treat O
. O

The B-Premise
overall I-Premise
response I-Premise
rate I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
with I-Premise
erlotinib I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
24 I-Premise
% I-Premise
versus I-Premise
5 I-Premise
% I-Premise
";" I-Premise
p=0.0025 I-Premise
) I-Premise
. I-Premise

All O
completed O
questionnaires O
3 O
times O
. O

These O
results O
were O
robust O
to O
sensitivity O
analysis O
. O

The O
primary O
endpoint O
was O
biochemical O
relapse O
according O
to O
the O
modified O
1997-American O
Society O
for O
Therapeutic O
Radiology O
and O
Oncology O
and O
Phoenix O
definitions O
. O

HRQOL O
was O
assessed O
at O
baseline O
, O
at O
end O
of O
cycle O
2 O
, O
and O
4 O
, O
6 O
, O
and O
9 O
months O
after O
completion O
of O
RT O
using O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
QLQ-C30 O
) O
and O
the O
EORTC O
QLQ O
Head O
and O
Neck O
Cancer-Specific O
Module O
( O
EORTC O
QLQ-H O
& O
amp O
";" O
N35 O
) O
. O

A O
total O
of O
60 O
patients O
were O
enrolled O
: O
41 O
patients O
diagnosed O
with O
resectable O
and O
19 O
patients O
diagnosed O
with O
unresectable O
pancreatic O
cancer O
. O

The O
importance O
of O
parallel O
evaluation O
of O
survival O
and O
quality O
of O
life O
( O
QoL O
) O
has O
been O
recognized O
as O
fundamental O
and O
the O
aim O
was O
to O
assess O
QoL O
and O
quality O
adjusted O
survival O
. O

During B-Claim
radiotherapy I-Claim
, I-Claim
both I-Claim
interventions I-Claim
positively I-Claim
influenced I-Claim
outcomes I-Claim
";" I-Claim
dietary B-Claim
counseling I-Claim
was I-Claim
of I-Claim
similar I-Claim
or I-Claim
higher I-Claim
benefit I-Claim
, I-Claim
whereas I-Claim
even I-Claim
3 I-Claim
months I-Claim
after I-Claim
RT I-Claim
, I-Claim
it I-Claim
was I-Claim
the I-Claim
only I-Claim
method I-Claim
to I-Claim
sustain I-Claim
a I-Claim
significant I-Claim
impact I-Claim
on I-Claim
patient I-Claim
outcomes I-Claim
. I-Claim

Using O
a O
computer-generated O
randomisation O
sequence O
, O
we O
randomly O
allocated O
patients O
to O
one O
of O
three O
groups O
( O
1:1:1 O
";" O
stratified O
by O
tumour O
site O
[ O
urological O
, O
gynaecological O
, O
or O
gastrointestinal O
] O
, O
and O
degree O
of O
bowel O
dysfunction O
[ O
IBDQ-B O
score O
< O
60 O
vs O
60-70 O
] O
) O
: O
usual O
care O
( O
a O
detailed O
self-help O
booklet O
) O
, O
gastroenterologist-led O
algorithm-based O
treatment O
, O
or O
nurse-led O
algorithm-based O
treatment O
. O

Patients B-Premise
with I-Premise
PSA I-Premise
nadir I-Premise
≤ I-Premise
0.2 I-Premise
ng/ml I-Premise
, I-Premise
though I-Premise
had I-Premise
significantly I-Premise
higher I-Premise
2-year I-Premise
risk I-Premise
of I-Premise
progression I-Premise
compared I-Premise
to I-Premise
CAD I-Premise
( I-Premise
53 I-Premise
% I-Premise
vs. I-Premise
31 I-Premise
% I-Premise
( I-Premise
P I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Patients O
with O
various O
malignancies O
participated O
in O
the O
RCT O
( O
n O
= O
210 O
) O
. O

Outcomes O
were O
medical O
effects O
, O
quality O
of O
life O
, O
and O
costs O
. O

Grade B-Premise
3/4 I-Premise
neutropenia I-Premise
was I-Premise
frequent I-Premise
in I-Premise
both I-Premise
groups I-Premise
, I-Premise
although B-Premise
febrile I-Premise
neutropenia I-Premise
and I-Premise
infections I-Premise
were I-Premise
more I-Premise
frequent I-Premise
for I-Premise
patients I-Premise
taking I-Premise
AT I-Premise
( I-Premise
respectively I-Premise
, I-Premise
33 I-Premise
% I-Premise
v I-Premise
10 I-Premise
% I-Premise
, I-Premise
P I-Premise
< I-Premise
.001 I-Premise
";" I-Premise
8 I-Premise
% I-Premise
v I-Premise
2 I-Premise
% I-Premise
, I-Premise
P I-Premise
=.01 I-Premise
) I-Premise
. I-Premise

Inclusion O
criteria O
were O
inoperable O
, O
disease O
too O
advanced O
for O
curative O
radiotherapy O
, O
and O
chest O
symptoms O
or O
central O
tumor O
threatening O
the O
airways O
. O

Multivariable B-Premise
repeated I-Premise
measures I-Premise
modeling I-Premise
demonstrated I-Premise
that I-Premise
treatment I-Premise
arm I-Premise
, I-Premise
time I-Premise
point I-Premise
, I-Premise
age I-Premise
, I-Premise
and I-Premise
tamoxifen I-Premise
use I-Premise
were I-Premise
significantly I-Premise
associated I-Premise
with I-Premise
symptom I-Premise
severity I-Premise
( I-Premise
all I-Premise
P I-Premise
values I-Premise
< I-Premise
.002 I-Premise
) I-Premise
. I-Premise

To O
determine O
the O
effect O
of O
a O
nursing-led O
intervention O
on O
quality O
of O
life O
, O
symptom O
intensity O
, O
mood O
, O
and O
resource O
use O
in O
patients O
with O
advanced O
cancer O
. O

The B-Premise
HgB I-Premise
responders I-Premise
( I-Premise
irrespective I-Premise
of I-Premise
treatment I-Premise
arm I-Premise
) I-Premise
had I-Premise
a I-Premise
mean I-Premise
change I-Premise
in I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy I-Premise
( I-Premise
FACT I-Premise
) I-Premise
fatigue I-Premise
score I-Premise
from I-Premise
a I-Premise
baseline I-Premise
of I-Premise
+5.1 I-Premise
compared I-Premise
with I-Premise
-2.1 I-Premise
for I-Premise
the I-Premise
nonresponders I-Premise
( I-Premise
P I-Premise
= I-Premise
.006 I-Premise
) I-Premise
. I-Premise

The B-Premise
final I-Premise
multivariate I-Premise
model I-Premise
for I-Premise
response I-Premise
selected I-Premise
DFI I-Premise
( I-Premise
P=0.009 I-Premise
) I-Premise
, I-Premise
multiple I-Premise
sites I-Premise
of I-Premise
visceral I-Premise
disease I-Premise
( I-Premise
P=0.037 I-Premise
) I-Premise
and I-Premise
dyspnoea I-Premise
( I-Premise
P= I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
using I-Premise
forward I-Premise
selection I-Premise
, I-Premise
but B-Premise
model I-Premise
instability I-Premise
was I-Premise
indicated I-Premise
by I-Premise
the I-Premise
inclusion I-Premise
of I-Premise
fatigue I-Premise
and I-Premise
emotional I-Premise
function I-Premise
in I-Premise
the I-Premise
final I-Premise
model I-Premise
when I-Premise
backward I-Premise
selection I-Premise
was I-Premise
used I-Premise
. I-Premise

These B-Claim
results I-Claim
support I-Claim
the I-Claim
efficacy I-Claim
and I-Claim
safety I-Claim
of I-Claim
an I-Claim
every-2-weeks I-Claim
treatment I-Claim
with I-Claim
gemcitabine I-Claim
plus I-Claim
cisplatin I-Claim
. I-Claim

The B-Premise
5-year I-Premise
overall I-Premise
mortality I-Premise
for I-Premise
short-term I-Premise
and I-Premise
long-term I-Premise
suppression I-Premise
was I-Premise
19.0 I-Premise
% I-Premise
and I-Premise
15.2 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
the O
observed O
hazard O
ratio O
was O
1.42 O
( O
upper O
95.71 O
% O
confidence O
limit O
, O
1.79 O
";" O
P=0.65 O
for O
noninferiority O
) O
. O

Post-treatment B-Premise
symptoms I-Premise
were I-Premise
increased I-Premise
above I-Premise
baseline I-Premise
for I-Premise
all I-Premise
treatments I-Premise
. I-Premise

Comparison O
of O
Faslodex O
in O
Recurrent O
or O
Metastatic O
Breast O
Cancer O
( O
CONFIRM O
) O
is O
a O
double-blind O
, O
parallel-group O
, O
multicenter O
, O
phase O
III O
study O
. O

Two O
patients O
were O
excluded O
from O
the O
final O
analysis O
: O
One O
patient O
suspended O
ghrelin O
administration O
because O
of O
excessive O
diaphoresis O
, O
and O
another O
patient O
in O
the O
placebo O
group O
failed O
to O
monitor O
the O
self-questionnaire O
. O

However O
, O
QOL B-Claim
scores I-Claim
were I-Claim
not I-Claim
significantly I-Claim
different I-Claim
among I-Claim
the I-Claim
regimens I-Claim
. I-Claim

Patients B-Premise
receiving I-Premise
the I-Premise
intervention I-Premise
demonstrated I-Premise
statistically I-Premise
significant I-Premise
improvement I-Premise
( I-Premise
P I-Premise
=.0004 I-Premise
) I-Premise
in I-Premise
menopausal I-Premise
symptoms I-Premise
but I-Premise
no I-Premise
significant I-Premise
change I-Premise
in I-Premise
vitality I-Premise
( I-Premise
P I-Premise
=.77 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
also I-Premise
no I-Premise
differences I-Premise
in I-Premise
the I-Premise
frequency I-Premise
of I-Premise
incompletely I-Premise
infarcted I-Premise
leiomyomas I-Premise
, I-Premise
degree I-Premise
of I-Premise
improvement I-Premise
in I-Premise
symptom I-Premise
score I-Premise
, I-Premise
patient I-Premise
satisfaction I-Premise
, I-Premise
or I-Premise
QOL I-Premise
. I-Premise

There O
are O
very O
few O
randomized O
controlled O
studies O
on O
exercise O
in O
cancer O
patients O
. O

Results B-Claim
of I-Claim
this I-Claim
randomized I-Claim
study I-Claim
incorporating I-Claim
prospective I-Claim
QOL I-Claim
measurements I-Claim
suggested I-Claim
that I-Claim
in I-Claim
patients I-Claim
with I-Claim
locally I-Claim
advanced I-Claim
NSCLC I-Claim
, I-Claim
analyzing I-Claim
QOL I-Claim
data I-Claim
by I-Claim
either I-Claim
gender I-Claim
or I-Claim
performance I-Claim
status I-Claim
alone I-Claim
may I-Claim
not I-Claim
accurately I-Claim
reflect I-Claim
how I-Claim
these I-Claim
factors I-Claim
depend I-Claim
upon I-Claim
each I-Claim
another I-Claim
. I-Claim

The B-Premise
clinical I-Premise
results I-Premise
found I-Premise
raltitrexed I-Premise
and I-Premise
cisplatin I-Premise
to I-Premise
be I-Premise
superior I-Premise
to I-Premise
cisplatin I-Premise
with I-Premise
regard I-Premise
to I-Premise
overall I-Premise
survival I-Premise
( I-Premise
P I-Premise
= I-Premise
.048 I-Premise
) I-Premise
. I-Premise

In B-Claim
conclusion I-Claim
, I-Claim
this I-Claim
first I-Claim
randomized I-Claim
study I-Claim
did I-Claim
not I-Claim
demonstrate I-Claim
any I-Claim
significant I-Claim
improvement I-Claim
of I-Claim
using I-Claim
estramustine I-Claim
in I-Claim
addition I-Claim
to I-Claim
conventional I-Claim
radiotherapy I-Claim
, I-Claim
however B-Claim
, I-Claim
a I-Claim
trend I-Claim
for I-Claim
a I-Claim
positive I-Claim
response I-Claim
for I-Claim
the I-Claim
estramustine I-Claim
group I-Claim
was I-Claim
found I-Claim
in I-Claim
patients I-Claim
with I-Claim
grade I-Claim
III I-Claim
glioma I-Claim
. I-Claim

Thirty-eight B-Premise
patients I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
and I-Premise
58 I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
, I-Premise
suffered I-Premise
breakthrough I-Premise
pain I-Premise
on I-Premise
day I-Premise
3 I-Premise
( I-Premise
P I-Premise
< I-Premise
0·001 I-Premise
) I-Premise
. I-Premise

The B-Premise
difference I-Premise
in I-Premise
PFS I-Premise
between I-Premise
three I-Premise
and I-Premise
four I-Premise
cycles I-Premise
is I-Premise
-1.0 I-Premise
% I-Premise
( I-Premise
80 I-Premise
% I-Premise
confidence I-Premise
limit I-Premise
[ I-Premise
CL I-Premise
] I-Premise
, I-Premise
-3.8 I-Premise
% I-Premise
, I-Premise
+1.8 I-Premise
% I-Premise
) I-Premise
. I-Premise

cryoablation B-Premise
was I-Premise
associated I-Premise
with I-Premise
more I-Premise
acute I-Premise
urinary I-Premise
dysfunction I-Premise
( I-Premise
mean I-Premise
PCI I-Premise
urinary I-Premise
function I-Premise
cryoablation=69.4 I-Premise
";" I-Premise
mean I-Premise
EBRT=90.7 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
which I-Premise
resolved I-Premise
over I-Premise
time I-Premise
. I-Premise

Toxicity B-Premise
of I-Premise
HDC I-Premise
has I-Premise
a I-Premise
strong I-Premise
negative I-Premise
impact I-Premise
on I-Premise
patients I-Premise
' I-Premise
QOL I-Premise
during I-Premise
the I-Premise
treatment I-Premise
phase I-Premise
. I-Premise

Numeric B-Premise
rating I-Premise
scale I-Premise
scores I-Premise
for I-Premise
pain I-Premise
intensity I-Premise
in I-Premise
group I-Premise
1 I-Premise
and I-Premise
group I-Premise
2 I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
than I-Premise
those I-Premise
in I-Premise
group I-Premise
3 I-Premise
at I-Premise
T I-Premise
( I-Premise
0-12 I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
";" I-Premise
T I-Premise
( I-Premise
12-24 I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
";" I-Premise
and I-Premise
T I-Premise
( I-Premise
24-48 I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

In O
the O
comparison O
of O
responders O
versus O
patients O
with O
both O
SD O
( O
6m O
) O
and O
PD O
, O
responders B-Premise
indicated I-Premise
better I-Premise
physical I-Premise
well-being I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
4 I-Premise
) I-Premise
and I-Premise
mood I-Premise
( I-Premise
P I-Premise
=.02 I-Premise
) I-Premise
at I-Premise
month I-Premise
3 I-Premise
. I-Premise

In B-Claim
nonrandomized I-Claim
studies I-Claim
involving I-Claim
patients I-Claim
with I-Claim
different I-Claim
tumor I-Claim
types I-Claim
including I-Claim
non-small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
, I-Claim
ATP I-Claim
infusion I-Claim
appeared I-Claim
to I-Claim
inhibit I-Claim
loss I-Claim
of I-Claim
weight I-Claim
and I-Claim
deterioration I-Claim
of I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
and I-Claim
performance I-Claim
status I-Claim
. I-Claim

Quality B-Premise
of I-Premise
life I-Premise
was I-Premise
maintained I-Premise
better I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
three I-Premise
cycles I-Premise
";" I-Premise
no B-Premise
differences I-Premise
were I-Premise
detected I-Premise
between I-Premise
3 I-Premise
and I-Premise
5 I-Premise
days I-Premise
of I-Premise
treatment I-Premise
. I-Premise

Treatment B-Premise
with I-Premise
docetaxel-carboplatin I-Premise
was I-Premise
associated I-Premise
with I-Premise
statistically I-Premise
significantly I-Premise
more I-Premise
grade I-Premise
3-4 I-Premise
neutropenia I-Premise
( I-Premise
94 I-Premise
% I-Premise
versus I-Premise
84 I-Premise
% I-Premise
, I-Premise
difference I-Premise
= I-Premise
11 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
7 I-Premise
% I-Premise
to I-Premise
14 I-Premise
% I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
and I-Premise
neutropenic I-Premise
complications I-Premise
than I-Premise
treatment I-Premise
with I-Premise
paclitaxel-carboplatin I-Premise
, I-Premise
although B-Premise
myelosuppression I-Premise
did I-Premise
not I-Premise
influence I-Premise
dose I-Premise
delivery I-Premise
or I-Premise
patient I-Premise
safety I-Premise
. I-Premise

The B-Premise
quality-of-life I-Premise
questionnaire I-Premise
results I-Premise
before I-Premise
and I-Premise
5 I-Premise
years I-Premise
after I-Premise
treatment I-Premise
were I-Premise
available I-Premise
for I-Premise
103 I-Premise
patients I-Premise
with I-Premise
no I-Premise
differences I-Premise
found I-Premise
between I-Premise
the I-Premise
-70 I-Premise
and I-Premise
80-Gy I-Premise
arms I-Premise
. I-Premise

Nausea B-Premise
and I-Premise
vomiting I-Premise
frequency I-Premise
, I-Premise
duration I-Premise
, I-Premise
and I-Premise
distress I-Premise
were I-Premise
lower I-Premise
for I-Premise
experimental I-Premise
group I-Premise
members I-Premise
, I-Premise
although B-Premise
a I-Premise
high I-Premise
attrition I-Premise
rate I-Premise
( I-Premise
50 I-Premise
% I-Premise
) I-Premise
resulted I-Premise
in I-Premise
insufficient I-Premise
power I-Premise
to I-Premise
detect I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
over I-Premise
time I-Premise
. I-Premise

At B-Premise
5 I-Premise
years I-Premise
, I-Premise
the I-Premise
prevalence I-Premise
of I-Premise
new I-Premise
fibroid I-Premise
was I-Premise
60 I-Premise
% I-Premise
in I-Premise
the I-Premise
myomectomy I-Premise
group I-Premise
and I-Premise
7 I-Premise
% I-Premise
in I-Premise
the I-Premise
UAE I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0.008 I-Premise
) I-Premise
. I-Premise

The B-Claim
data I-Claim
suggest I-Claim
that I-Claim
combination I-Claim
therapy I-Claim
might I-Claim
provide I-Claim
another I-Claim
treatment I-Claim
option I-Claim
for I-Claim
SUI I-Claim
in I-Claim
men I-Claim
that I-Claim
might I-Claim
increase I-Claim
the I-Claim
percentage I-Claim
of I-Claim
early I-Claim
postsurgery I-Claim
continence I-Claim
. I-Claim

Monthly B-Claim
infusion I-Claim
of I-Claim
pamidronate I-Claim
30 I-Claim
mg I-Claim
should I-Claim
be I-Claim
the I-Claim
recommended I-Claim
dose I-Claim
for I-Claim
prevention I-Claim
of I-Claim
bone I-Claim
disease I-Claim
in I-Claim
patients I-Claim
with I-Claim
multiple I-Claim
myeloma I-Claim
. I-Claim

Time B-Premise
to I-Premise
response I-Premise
and I-Premise
ORR I-Premise
favor I-Premise
TCF I-Premise
over I-Premise
TC I-Premise
for I-Premise
further I-Premise
evaluation I-Premise
, I-Premise
particularly I-Premise
in I-Premise
the I-Premise
neoadjuvant I-Premise
setting I-Premise
. I-Premise

Although B-Premise
other I-Premise
group I-Premise
× I-Premise
time I-Premise
interactions I-Premise
were I-Premise
not I-Premise
significant I-Premise
, I-Premise
overall I-Premise
adjusted I-Premise
effect I-Premise
sizes I-Premise
for I-Premise
all I-Premise
sleep I-Premise
variables I-Premise
as I-Premise
well I-Premise
as I-Premise
for I-Premise
fatigue I-Premise
, I-Premise
depression I-Premise
, I-Premise
anxiety I-Premise
, I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
ranged I-Premise
from I-Premise
small I-Premise
to I-Premise
large I-Premise
. I-Premise

No B-Premise
evidence I-Premise
of I-Premise
a I-Premise
difference I-Premise
was I-Premise
observed I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
groups I-Premise
in I-Premise
terms I-Premise
of I-Premise
activity I-Premise
level I-Premise
, I-Premise
anxiety I-Premise
, I-Premise
depression I-Premise
, I-Premise
and I-Premise
psychological I-Premise
distress I-Premise
, I-Premise
as I-Premise
recorded I-Premise
by I-Premise
the I-Premise
patients I-Premise
. I-Premise

However B-Claim
, I-Claim
the I-Claim
trend I-Claim
in I-Claim
RR I-Claim
, I-Claim
PFS I-Claim
, I-Claim
and I-Claim
OS I-Claim
favors I-Claim
PC I-Claim
. I-Claim

Neither B-Claim
FU24h I-Claim
+ I-Claim
LV I-Claim
nor I-Claim
FU24h I-Claim
prolong I-Claim
survival I-Claim
, I-Claim
relative I-Claim
to I-Claim
bolus I-Claim
FU I-Claim
+ I-Claim
LV I-Claim
. I-Claim

The B-Premise
median I-Premise
survival I-Premise
reached I-Premise
8 I-Premise
months I-Premise
in I-Premise
Study I-Premise
A I-Premise
and I-Premise
9 I-Premise
months I-Premise
in I-Premise
Study I-Premise
B I-Premise
. I-Premise

After B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
23 I-Premise
months I-Premise
, I-Premise
both I-Premise
groups I-Premise
had I-Premise
similar I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
medians I-Premise
of I-Premise
15.0 I-Premise
months I-Premise
for I-Premise
docetaxel-carboplatin I-Premise
and I-Premise
14.8 I-Premise
months I-Premise
for I-Premise
paclitaxel-carboplatin I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
docetaxel-paclitaxel I-Premise
= I-Premise
0.97 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
0.83 I-Premise
to I-Premise
1.13 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.707 I-Premise
) I-Premise
, I-Premise
overall I-Premise
survival I-Premise
rates I-Premise
at I-Premise
2 I-Premise
years I-Premise
( I-Premise
64.2 I-Premise
% I-Premise
and I-Premise
68.9 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
HR I-Premise
= I-Premise
1.13 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.92 I-Premise
to I-Premise
1.39 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.238 I-Premise
) I-Premise
, I-Premise
and I-Premise
objective I-Premise
tumor I-Premise
( I-Premise
58.7 I-Premise
% I-Premise
and I-Premise
59.5 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
difference I-Premise
between I-Premise
docetaxel I-Premise
and I-Premise
paclitaxel I-Premise
= I-Premise
-0.8 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-8.6 I-Premise
% I-Premise
to I-Premise
7.1 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.868 I-Premise
) I-Premise
and I-Premise
CA-125 I-Premise
( I-Premise
75.8 I-Premise
% I-Premise
and I-Premise
76.8 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
difference I-Premise
docetaxel-paclitaxel I-Premise
= I-Premise
-1.0 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-7.2 I-Premise
% I-Premise
to I-Premise
5.1 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.794 I-Premise
) I-Premise
response I-Premise
rates I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
VBT I-Premise
group I-Premise
reported I-Premise
better I-Premise
social I-Premise
functioning I-Premise
( I-Premise
P I-Premise
< I-Premise
.002 I-Premise
) I-Premise
and I-Premise
lower I-Premise
symptom I-Premise
scores I-Premise
for I-Premise
diarrhea I-Premise
, I-Premise
fecal I-Premise
leakage I-Premise
, I-Premise
the I-Premise
need I-Premise
to I-Premise
stay I-Premise
close I-Premise
to I-Premise
the I-Premise
toilet I-Premise
, I-Premise
and I-Premise
limitation I-Premise
in I-Premise
daily I-Premise
activities I-Premise
because I-Premise
of I-Premise
bowel I-Premise
symptoms I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Letrozole B-Claim
did I-Claim
not I-Claim
have I-Claim
an I-Claim
adverse I-Claim
impact I-Claim
on I-Claim
overall I-Claim
QOL I-Claim
. I-Claim

Despite B-Claim
small I-Claim
numbers I-Claim
, I-Claim
the I-Claim
main I-Claim
effect I-Claim
size I-Claim
was I-Claim
robust I-Claim
. I-Claim

Overall B-Premise
response I-Premise
was I-Premise
54 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
44.1 I-Premise
% I-Premise
-63.9 I-Premise
% I-Premise
) I-Premise
with I-Premise
PVI I-Premise
5-FU I-Premise
+ I-Premise
MMC I-Premise
compared I-Premise
to I-Premise
38 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
28.3 I-Premise
% I-Premise
-47.7 I-Premise
% I-Premise
) I-Premise
for I-Premise
PVI I-Premise
5-FU I-Premise
alone I-Premise
( I-Premise
P I-Premise
= I-Premise
0.024 I-Premise
) I-Premise
. I-Premise

However B-Claim
, I-Claim
exercise I-Claim
is I-Claim
not I-Claim
better I-Claim
than I-Claim
progressive I-Claim
relaxation I-Claim
training I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
fatigue I-Claim
in I-Claim
this I-Claim
setting I-Claim
. I-Claim

However O
, O
there B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
of I-Premise
QOL I-Premise
scores I-Premise
and I-Premise
postoperative I-Premise
complication I-Premise
scores I-Premise
between I-Premise
the I-Premise
2 I-Premise
reconstruction I-Premise
groups I-Premise
. I-Premise

The B-Premise
rate I-Premise
of I-Premise
endometrial I-Premise
cancer I-Premise
was I-Premise
increased I-Premise
in I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
( I-Premise
risk I-Premise
ratio I-Premise
= I-Premise
2.53 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
= I-Premise
1.35-4.97 I-Premise
) I-Premise
";" I-Premise
this I-Premise
increased I-Premise
risk I-Premise
occurred I-Premise
predominantly I-Premise
in I-Premise
women I-Premise
aged I-Premise
50 I-Premise
years I-Premise
or I-Premise
older I-Premise
. I-Premise

For B-Premise
the I-Premise
stage I-Premise
IV I-Premise
subgroup I-Premise
, I-Premise
the I-Premise
median I-Premise
survival I-Premise
time I-Premise
for I-Premise
etoposide I-Premise
plus I-Premise
cisplatin I-Premise
was I-Premise
7.6 I-Premise
months I-Premise
compared I-Premise
with I-Premise
8.9 I-Premise
months I-Premise
for I-Premise
paclitaxel I-Premise
( I-Premise
P I-Premise
=.246 I-Premise
) I-Premise
. I-Premise

Significant B-Premise
effects I-Premise
were I-Premise
seen I-Premise
on I-Premise
vitality I-Premise
( I-Premise
effect I-Premise
size I-Premise
0.55 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.27 I-Premise
to I-Premise
0.82 I-Premise
) I-Premise
, I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
0.37 I-Premise
, I-Premise
0.09 I-Premise
to I-Premise
0.65 I-Premise
) I-Premise
, I-Premise
role I-Premise
physical I-Premise
( I-Premise
0.37 I-Premise
, I-Premise
0.10 I-Premise
to I-Premise
0.64 I-Premise
) I-Premise
, I-Premise
role I-Premise
emotional I-Premise
( I-Premise
0.32 I-Premise
, I-Premise
0.05 I-Premise
to I-Premise
0.59 I-Premise
) I-Premise
, I-Premise
and I-Premise
mental I-Premise
health I-Premise
( I-Premise
0.28 I-Premise
, I-Premise
0.02 I-Premise
to I-Premise
0.56 I-Premise
) I-Premise
scores I-Premise
. I-Premise

In B-Premise
both I-Premise
groups I-Premise
, I-Premise
the I-Premise
hot I-Premise
flash I-Premise
score I-Premise
peaked I-Premise
at I-Premise
3 I-Premise
months I-Premise
and I-Premise
decreased I-Premise
thereafter I-Premise
. I-Premise

A B-Claim
multidimensional I-Claim
rehabilitation I-Claim
program I-Claim
has I-Claim
statistically I-Claim
and I-Claim
clinically I-Claim
relevant I-Claim
beneficial I-Claim
effects I-Claim
on I-Claim
health-related I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
exercise I-Claim
capacity I-Claim
, I-Claim
and I-Claim
muscle I-Claim
force I-Claim
in I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
different I-Claim
diagnoses I-Claim
. I-Claim

Measurable B-Claim
improvement I-Claim
in I-Claim
a I-Claim
general I-Claim
QOL I-Claim
measure I-Claim
was I-Claim
not I-Claim
demonstrated I-Claim
. I-Claim

However B-Claim
, I-Claim
the I-Claim
intervention I-Claim
was I-Claim
not I-Claim
found I-Claim
to I-Claim
reduce I-Claim
the I-Claim
risk I-Claim
of I-Claim
cancer I-Claim
recurrence I-Claim
and I-Claim
death I-Claim
. I-Claim

When B-Premise
group I-Premise
1 I-Premise
with I-Premise
group I-Premise
2 I-Premise
were I-Premise
compared I-Premise
, I-Premise
numeric I-Premise
rating I-Premise
scale I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
group I-Premise
1 I-Premise
than I-Premise
in I-Premise
group I-Premise
2 I-Premise
during I-Premise
the I-Premise
period I-Premise
of I-Premise
T I-Premise
( I-Premise
0-12 I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
but B-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
at I-Premise
T I-Premise
( I-Premise
12-24 I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
.68 I-Premise
) I-Premise
and I-Premise
T I-Premise
( I-Premise
24-48 I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
.10 I-Premise
) I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
was I-Premise
well I-Premise
preserved I-Premise
in I-Premise
the I-Premise
euthyroid I-Premise
group I-Premise
, I-Premise
compared I-Premise
with I-Premise
the I-Premise
hypothyroid I-Premise
group I-Premise
, I-Premise
as I-Premise
demonstrated I-Premise
by I-Premise
their I-Premise
lower I-Premise
pretreatment I-Premise
scores I-Premise
on I-Premise
the I-Premise
Billewicz I-Premise
scale I-Premise
for I-Premise
hypothyroid I-Premise
signs I-Premise
and I-Premise
symptoms I-Premise
, I-Premise
27 I-Premise
+/- I-Premise
7 I-Premise
vs. I-Premise
18 I-Premise
+/- I-Premise
4 I-Premise
( I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
and I-Premise
their I-Premise
significantly I-Premise
higher I-Premise
Short I-Premise
Form-36 I-Premise
Health I-Premise
Assessment I-Premise
Scale I-Premise
scores I-Premise
in I-Premise
five I-Premise
of I-Premise
eight I-Premise
categories I-Premise
. I-Premise

Among B-Premise
the I-Premise
clinical I-Premise
outcome I-Premise
measures I-Premise
, I-Premise
QOL I-Premise
score I-Premise
improvement I-Premise
was I-Premise
greater I-Premise
for I-Premise
UAE I-Premise
with I-Premise
TAGMs I-Premise
compared I-Premise
with I-Premise
PVA I-Premise
( I-Premise
49.0 I-Premise
vs I-Premise
27.9 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
, I-Premise
but B-Premise
no I-Premise
other I-Premise
differences I-Premise
were I-Premise
noted I-Premise
. I-Premise

Intent-to-treat B-Premise
CR I-Premise
rates I-Premise
for I-Premise
patients I-Premise
randomized I-Premise
to I-Premise
HDCT I-Premise
and I-Premise
AT I-Premise
were I-Premise
12.5 I-Premise
% I-Premise
and I-Premise
11.1 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
= I-Premise
.84 I-Premise
) I-Premise
. I-Premise

Overall B-Claim
survival I-Claim
was I-Claim
not I-Claim
statistically I-Claim
significantly I-Claim
improved I-Claim
at I-Claim
this I-Claim
time I-Claim
. I-Claim

Treatment B-Premise
arms I-Premise
did I-Premise
not I-Premise
differ I-Premise
regarding I-Premise
withdrawal I-Premise
rate I-Premise
and I-Premise
the I-Premise
experience I-Premise
of I-Premise
( I-Premise
serious I-Premise
) I-Premise
adverse I-Premise
events I-Premise
. I-Premise

Exemestane B-Premise
patients I-Premise
reported I-Premise
more I-Premise
bone/muscle I-Premise
aches I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
, I-Premise
vaginal I-Premise
dryness I-Premise
( I-Premise
P I-Premise
= I-Premise
.0004 I-Premise
) I-Premise
, I-Premise
and I-Premise
difficulty I-Premise
sleeping I-Premise
( I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
who I-Premise
received I-Premise
the I-Premise
800-mg/d I-Premise
dose I-Premise
fell I-Premise
between I-Premise
the I-Premise
low- I-Premise
and I-Premise
high-dose I-Premise
arms I-Premise
in I-Premise
reported I-Premise
intensity I-Premise
of I-Premise
drug I-Premise
side I-Premise
effects I-Premise
, I-Premise
but B-Premise
responded I-Premise
similarly I-Premise
to I-Premise
those I-Premise
in I-Premise
the I-Premise
160-mg/d I-Premise
group I-Premise
in I-Premise
terms I-Premise
of I-Premise
physical I-Premise
functioning I-Premise
, I-Premise
psychologic I-Premise
distress I-Premise
, I-Premise
and I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise

However B-Claim
, I-Claim
modifications I-Claim
are I-Claim
needed I-Claim
in I-Claim
future I-Claim
randomized I-Claim
trials I-Claim
to I-Claim
reduce I-Claim
the I-Claim
rate I-Claim
of I-Claim
premature I-Claim
termination I-Claim
and I-Claim
to I-Claim
improve I-Claim
long-term I-Claim
maintenance I-Claim
of I-Claim
gains I-Claim
. I-Claim

Patients B-Claim
with I-Claim
low I-Claim
PSA I-Claim
nadir I-Claim
do I-Claim
significantly I-Claim
worse I-Claim
with I-Claim
IAD I-Claim
compared I-Claim
with I-Claim
CAD I-Claim
. I-Claim

The B-Claim
use I-Claim
of I-Claim
home-based I-Claim
assessments I-Claim
by I-Claim
a I-Claim
research I-Claim
nurse I-Claim
proved I-Claim
to I-Claim
be I-Claim
an I-Claim
effective I-Claim
way I-Claim
of I-Claim
obtaining I-Claim
high-quality I-Claim
data I-Claim
. I-Claim

Among B-Premise
responding I-Premise
patients I-Premise
, I-Premise
mean I-Premise
scores I-Premise
generally I-Premise
improved I-Premise
from I-Premise
time I-Premise
of I-Premise
response I-Premise
to I-Premise
end-of-treatment I-Premise
assessment I-Premise
, I-Premise
substantially I-Premise
driven I-Premise
by I-Premise
patients I-Premise
achieving I-Premise
complete I-Premise
response I-Premise
( I-Premise
CR I-Premise
) I-Premise
. I-Premise

Addition B-Claim
of I-Claim
bevacizumab I-Claim
to I-Claim
FU/LV I-Claim
as I-Claim
first-line I-Claim
therapy I-Claim
in I-Claim
CRC I-Claim
patients I-Claim
who I-Claim
were I-Claim
not I-Claim
considered I-Claim
optimal I-Claim
candidates I-Claim
for I-Claim
first-line I-Claim
irinotecan I-Claim
treatment I-Claim
provided I-Claim
clinically I-Claim
significant I-Claim
patient I-Claim
benefit I-Claim
, I-Claim
including I-Claim
statistically I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
progression-free I-Claim
survival I-Claim
. I-Claim

Progression-free B-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
was I-Premise
significantly I-Premise
longer I-Premise
for I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
( I-Premise
median I-Premise
FU I-Premise
+ I-Premise
LV I-Premise
, I-Premise
4.0 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
3.4 I-Premise
to I-Premise
4.9 I-Premise
] I-Premise
";" I-Premise
FU24h I-Premise
, I-Premise
4.1 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
3.4 I-Premise
to I-Premise
5.0 I-Premise
] I-Premise
";" I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
5.6 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
4.4 I-Premise
to I-Premise
6.7 I-Premise
] I-Premise
";" I-Premise
P I-Premise
=.029 I-Premise
) I-Premise
. I-Premise

Group B-Premise
differences I-Premise
were I-Premise
smaller I-Premise
within I-Premise
the I-Premise
psychosocial I-Premise
domain I-Premise
, I-Premise
although B-Premise
trends I-Premise
were I-Premise
seen I-Premise
in I-Premise
favour I-Premise
of I-Premise
the I-Premise
chemotherapy I-Premise
group I-Premise
. I-Premise

PIDs B-Premise
were I-Premise
0·9 I-Premise
and I-Premise
0·3 I-Premise
in I-Premise
the I-Premise
oxycodone/paracetamol I-Premise
and I-Premise
placebo I-Premise
groups I-Premise
respectively I-Premise
, I-Premise
on I-Premise
day I-Premise
1 I-Premise
( I-Premise
P I-Premise
< I-Premise
0·001 I-Premise
) I-Premise
, I-Premise
and I-Premise
1·5 I-Premise
and I-Premise
0·3 I-Premise
respectively I-Premise
on I-Premise
day I-Premise
3 I-Premise
( I-Premise
P I-Premise
< I-Premise
0·001 I-Premise
) I-Premise
. I-Premise

EXE B-Claim
prolongs I-Claim
survival I-Claim
time I-Claim
, I-Claim
time I-Claim
to I-Claim
tumor I-Claim
progression I-Claim
, I-Claim
and I-Claim
time I-Claim
to I-Claim
treatment I-Claim
failure I-Claim
compared I-Claim
with I-Claim
MA I-Claim
and I-Claim
offers I-Claim
a I-Claim
well-tolerated I-Claim
treatment I-Claim
option I-Claim
for I-Claim
postmenopausal I-Claim
women I-Claim
with I-Claim
progressive I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
who I-Claim
experienced I-Claim
failure I-Claim
of I-Claim
tamoxifen I-Claim
. I-Claim

In O
this O
setting O
, O
local B-Claim
control I-Claim
and I-Claim
survival I-Claim
were I-Claim
essentially I-Claim
equal I-Claim
between I-Claim
the I-Claim
surgical I-Claim
and I-Claim
RT I-Claim
arms I-Claim
. I-Claim

Depression B-Claim
, I-Claim
anxiety I-Claim
, I-Claim
fatigue I-Claim
, I-Claim
and I-Claim
impaired I-Claim
wellbeing I-Claim
are I-Claim
common I-Claim
, I-Claim
important I-Claim
, I-Claim
and I-Claim
closely I-Claim
related I-Claim
in I-Claim
advanced I-Claim
cancer I-Claim
. I-Claim

Multivariate B-Premise
analysis I-Premise
showed I-Premise
a I-Premise
significant I-Premise
impact I-Premise
of I-Premise
duration I-Premise
of I-Premise
response/CR I-Premise
on I-Premise
improving I-Premise
global I-Premise
health I-Premise
status I-Premise
, I-Premise
pain I-Premise
, I-Premise
and I-Premise
appetite I-Premise
loss I-Premise
scores I-Premise
. I-Premise

Mean B-Premise
physical I-Premise
function I-Premise
at I-Premise
12 I-Premise
months I-Premise
was I-Premise
66 I-Premise
points I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
62·9-70·0 I-Premise
) I-Premise
in I-Premise
the I-Premise
90 I-Premise
mg I-Premise
group I-Premise
and I-Premise
68 I-Premise
points I-Premise
( I-Premise
64·6-71·4 I-Premise
) I-Premise
in I-Premise
the I-Premise
30 I-Premise
mg I-Premise
group I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
of I-Premise
difference I-Premise
-6·6 I-Premise
to I-Premise
3·3 I-Premise
";" I-Premise
p=0·52 I-Premise
) I-Premise
. I-Premise

The B-Premise
median I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
for I-Premise
the I-Premise
vaccine I-Premise
group I-Premise
was I-Premise
8.5 I-Premise
months I-Premise
, I-Premise
and I-Premise
8.0 I-Premise
months I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.075 I-Premise
) I-Premise
. I-Premise

Statistically B-Premise
significantly I-Premise
higher I-Premise
global I-Premise
QOL I-Premise
scores I-Premise
were I-Premise
found I-Premise
in I-Premise
PLD-treated I-Premise
patients I-Premise
at I-Premise
the I-Premise
first I-Premise
and I-Premise
second I-Premise
postbaseline I-Premise
QOL I-Premise
assessments I-Premise
. I-Premise

Grade B-Premise
3 I-Premise
or I-Premise
4 I-Premise
myelosuppressions I-Premise
were I-Premise
more I-Premise
frequent I-Premise
with I-Premise
GC I-Premise
( I-Premise
anaemia I-Premise
: I-Premise
14 I-Premise
% I-Premise
GC I-Premise
vs I-Premise
2 I-Premise
% I-Premise
PE I-Premise
";" I-Premise
leucopenia I-Premise
: I-Premise
32 I-Premise
% I-Premise
GC I-Premise
vs I-Premise
13 I-Premise
% I-Premise
PE I-Premise
";" I-Premise
thrombocytopenia I-Premise
: I-Premise
22 I-Premise
% I-Premise
GC I-Premise
vs I-Premise
4 I-Premise
% I-Premise
PE I-Premise
) I-Premise
, I-Premise
but B-Premise
these I-Premise
were I-Premise
not I-Premise
associated I-Premise
with I-Premise
increased I-Premise
hospital I-Premise
admissions I-Premise
, I-Premise
infections I-Premise
or I-Premise
fatalities I-Premise
. I-Premise

Consolidation B-Premise
chemotherapy I-Premise
was I-Premise
completed I-Premise
in I-Premise
75 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
. I-Premise

The B-Premise
use I-Premise
of I-Premise
IMRT I-Premise
did I-Premise
not I-Premise
correlate I-Premise
with I-Premise
pain I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
, O
but O
the B-Premise
presence I-Premise
of I-Premise
moist I-Premise
desquamation I-Premise
did I-Premise
significantly I-Premise
correlate I-Premise
with I-Premise
pain I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
and I-Premise
a I-Premise
reduced I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
= I-Premise
.003 I-Premise
) I-Premise
. I-Premise

The B-Claim
present I-Claim
analysis I-Claim
confirms I-Claim
that I-Claim
survival I-Claim
of I-Claim
men I-Claim
with I-Claim
metastatic I-Claim
HRPC I-Claim
is I-Claim
significantly I-Claim
longer I-Claim
after I-Claim
treatment I-Claim
with I-Claim
D3P I-Claim
than I-Claim
with I-Claim
MP I-Claim
. I-Claim

Although B-Premise
the I-Premise
change I-Premise
in I-Premise
fiber I-Premise
intake I-Premise
between I-Premise
the I-Premise
groups I-Premise
was I-Premise
not I-Premise
significant I-Premise
, I-Premise
there B-Premise
was I-Premise
a I-Premise
trend I-Premise
in I-Premise
the I-Premise
anticipated I-Premise
direction I-Premise
( I-Premise
P=0.083 I-Premise
) I-Premise
. I-Premise

The B-Claim
treatment I-Claim
choice I-Claim
for I-Claim
patients I-Claim
with I-Claim
inoperable I-Claim
esophageal I-Claim
cancer I-Claim
should I-Claim
be I-Claim
between I-Claim
a I-Claim
SEMS I-Claim
or I-Claim
a I-Claim
non-stent I-Claim
treatment I-Claim
after I-Claim
consideration I-Claim
has I-Claim
been I-Claim
given I-Claim
to I-Claim
both I-Claim
patient I-Claim
and I-Claim
tumor I-Claim
characteristics I-Claim
and I-Claim
clinician I-Claim
and I-Claim
patient I-Claim
preferences I-Claim
. I-Claim

The B-Premise
-1 I-Premise
and I-Premise
2-year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
31 I-Premise
and I-Premise
36 I-Premise
% I-Premise
, I-Premise
and I-Premise
10 I-Premise
and I-Premise
11 I-Premise
% I-Premise
respectively I-Premise
. I-Premise

Since B-Claim
the I-Claim
cost I-Claim
difference I-Claim
between I-Claim
the I-Claim
two I-Claim
treatments I-Claim
was I-Claim
only I-Claim
small I-Claim
, I-Claim
cost B-Claim
should I-Claim
not I-Claim
play I-Claim
a I-Claim
predominant I-Claim
role I-Claim
when I-Claim
deciding I-Claim
on I-Claim
the I-Claim
type I-Claim
of I-Claim
treatment I-Claim
assigned I-Claim
to I-Claim
patients I-Claim
with I-Claim
malignant I-Claim
GOO I-Claim
. I-Claim

There B-Claim
is I-Claim
substantial I-Claim
deterioration I-Claim
in I-Claim
QOL I-Claim
after I-Claim
curative-intent I-Claim
head-neck I-Claim
irradiation I-Claim
that I-Claim
gradually I-Claim
improves I-Claim
over I-Claim
time I-Claim
. I-Claim

In O
addition O
, O
tumor B-Claim
response I-Claim
was I-Claim
shown I-Claim
to I-Claim
have I-Claim
a I-Claim
beneficial I-Claim
effect I-Claim
on I-Claim
QoL I-Claim
indicators I-Claim
. I-Claim

Results B-Claim
suggest I-Claim
that I-Claim
change I-Claim
in I-Claim
self-efficacy I-Claim
for I-Claim
fat I-Claim
restriction I-Claim
partially I-Claim
explained I-Claim
the I-Claim
intervention I-Claim
's I-Claim
effect I-Claim
on I-Claim
fat I-Claim
intake I-Claim
( I-Claim
mean I-Claim
indirect I-Claim
effect I-Claim
= I-Claim
-0.28 I-Claim
) I-Claim
, I-Claim
and I-Claim
change I-Claim
in I-Claim
self-efficacy I-Claim
for I-Claim
F I-Claim
& I-Claim
V I-Claim
consumption I-Claim
partially I-Claim
explained I-Claim
the I-Claim
intervention I-Claim
's I-Claim
effect I-Claim
on I-Claim
daily I-Claim
F I-Claim
& I-Claim
V I-Claim
intake I-Claim
( I-Claim
mean I-Claim
indirect I-Claim
effect I-Claim
= I-Claim
.11 I-Claim
) I-Claim
. I-Claim

In B-Claim
cachectic I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
, I-Claim
oral I-Claim
melatonin I-Claim
20 I-Claim
mg I-Claim
at I-Claim
night I-Claim
did I-Claim
not I-Claim
improve I-Claim
appetite I-Claim
, I-Claim
weight I-Claim
, I-Claim
or I-Claim
quality I-Claim
of I-Claim
life I-Claim
compared I-Claim
with I-Claim
placebo I-Claim
. I-Claim

Quality B-Claim
of I-Claim
life I-Claim
during I-Claim
maintenance I-Claim
therapy I-Claim
with I-Claim
pemetrexed I-Claim
is I-Claim
similar I-Claim
to I-Claim
placebo I-Claim
, I-Claim
except B-Claim
for I-Claim
a I-Claim
small I-Claim
increase I-Claim
in I-Claim
loss I-Claim
of I-Claim
appetite I-Claim
, I-Claim
and I-Claim
significantly I-Claim
delayed I-Claim
worsening I-Claim
of I-Claim
pain I-Claim
and I-Claim
haemoptysis I-Claim
. I-Claim

Moreover O
, O
these B-Claim
two I-Claim
treatment I-Claim
protocols I-Claim
are I-Claim
inefficient I-Claim
and I-Claim
cost I-Claim
time I-Claim
in I-Claim
application I-Claim
. I-Claim

In B-Claim
patients I-Claim
with I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
who I-Claim
develop I-Claim
disease I-Claim
progression I-Claim
after I-Claim
treatment I-Claim
with I-Claim
nonsteroidal I-Claim
aromatase I-Claim
inhibitors I-Claim
, I-Claim
EVE I-Claim
+ I-Claim
EXE I-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
longer I-Claim
TDD I-Claim
in I-Claim
global I-Claim
HRQOL I-Claim
versus I-Claim
PBO I-Claim
+ I-Claim
EXE I-Claim
. I-Claim

Data B-Claim
suggest I-Claim
that I-Claim
the I-Claim
GE I-Claim
combination I-Claim
may I-Claim
improve I-Claim
clinical I-Claim
outcomes I-Claim
. I-Claim

Response B-Claim
proportion I-Claim
and I-Claim
survival I-Claim
did I-Claim
not I-Claim
improve I-Claim
significantly I-Claim
with I-Claim
the I-Claim
addition I-Claim
of I-Claim
13-CRA I-Claim
to I-Claim
IFNalpha2a I-Claim
therapy I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
RCC I-Claim
. I-Claim

AET B-Claim
did I-Claim
not I-Claim
significantly I-Claim
improve I-Claim
sleep I-Claim
quality I-Claim
in I-Claim
this I-Claim
heterogeneous I-Claim
sample I-Claim
of I-Claim
patients I-Claim
with I-Claim
lymphoma I-Claim
";" I-Claim
however B-Claim
, I-Claim
clinically I-Claim
identifiable I-Claim
subgroups I-Claim
appeared I-Claim
to I-Claim
benefit I-Claim
. I-Claim

A B-Claim
clinical I-Claim
assessment I-Claim
and I-Claim
intervention I-Claim
program I-Claim
for I-Claim
menopausal I-Claim
symptom I-Claim
management I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
is I-Claim
feasible I-Claim
and I-Claim
acceptable I-Claim
to I-Claim
patients I-Claim
, I-Claim
leading I-Claim
to I-Claim
reduction I-Claim
in I-Claim
symptoms I-Claim
and I-Claim
improvement I-Claim
in I-Claim
sexual I-Claim
functioning I-Claim
. I-Claim

Menopausal B-Claim
symptoms I-Claim
( I-Claim
e.g. I-Claim
, I-Claim
hot I-Claim
flashes I-Claim
, I-Claim
vaginal I-Claim
dryness I-Claim
, I-Claim
and I-Claim
stress I-Claim
urinary I-Claim
incontinence I-Claim
) I-Claim
are I-Claim
very I-Claim
common I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
and I-Claim
can I-Claim
not I-Claim
be I-Claim
managed I-Claim
with I-Claim
standard I-Claim
estrogen I-Claim
replacement I-Claim
therapy I-Claim
( I-Claim
ERT I-Claim
) I-Claim
in I-Claim
these I-Claim
patients I-Claim
. I-Claim

Overall O
, O
QoL B-Claim
scores I-Claim
were I-Claim
similar I-Claim
in I-Claim
the I-Claim
two I-Claim
treatment I-Claim
groups I-Claim
, I-Claim
but B-Claim
thalidomide I-Claim
was I-Claim
associated I-Claim
with I-Claim
less I-Claim
insomnia I-Claim
and I-Claim
diarrhea I-Claim
and I-Claim
more I-Claim
constipation I-Claim
and I-Claim
peripheral I-Claim
neuropathy I-Claim
. I-Claim

Patients B-Claim
given I-Claim
targeted I-Claim
intervention I-Claim
following I-Claim
a I-Claim
detailed I-Claim
clinical I-Claim
algorithm I-Claim
had I-Claim
better I-Claim
improvements I-Claim
in I-Claim
radiotherapy-induced I-Claim
gastrointestinal I-Claim
symptoms I-Claim
than I-Claim
did I-Claim
patients I-Claim
given I-Claim
usual I-Claim
care I-Claim
. I-Claim

Despite B-Claim
its I-Claim
efficacy I-Claim
in I-Claim
reducing I-Claim
locoregional I-Claim
recurrence I-Claim
, I-Claim
EBRT I-Claim
should I-Claim
be I-Claim
avoided I-Claim
in I-Claim
patients I-Claim
with I-Claim
low- I-Claim
and I-Claim
intermediate-risk I-Claim
EC I-Claim
. I-Claim

Both B-Claim
drugs I-Claim
could I-Claim
improve I-Claim
the I-Claim
QoL I-Claim
, I-Claim
but O
Gefitinib B-Claim
showed I-Claim
better I-Claim
overall I-Claim
results I-Claim
than I-Claim
Pemetrexed I-Claim
. I-Claim

Moist B-Claim
desquamation I-Claim
was I-Claim
correlated I-Claim
with I-Claim
increased I-Claim
pain I-Claim
and I-Claim
reduction I-Claim
in I-Claim
the I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Safe B-Claim
, I-Claim
effective I-Claim
non-hormonal I-Claim
treatments I-Claim
are I-Claim
needed I-Claim
. I-Claim

Somatostatin B-Claim
has I-Claim
been I-Claim
shown I-Claim
to I-Claim
have I-Claim
antimitotic I-Claim
activity I-Claim
in I-Claim
endocrine I-Claim
as I-Claim
well I-Claim
as I-Claim
in I-Claim
a I-Claim
variety I-Claim
of I-Claim
nonendocrine I-Claim
tumors I-Claim
. I-Claim

In O
conclusion O
, O
TMX B-Claim
does I-Claim
not I-Claim
prolong I-Claim
survival I-Claim
in I-Claim
patients I-Claim
with I-Claim
inoperable I-Claim
HCC I-Claim
and I-Claim
has I-Claim
an I-Claim
increasingly I-Claim
negative I-Claim
impact I-Claim
with I-Claim
increasing I-Claim
dose I-Claim
. I-Claim

While O
the B-Claim
short-term I-Claim
efficacy I-Claim
of I-Claim
degarelix I-Claim
and I-Claim
goserelin I-Claim
+ I-Claim
bicalutamide I-Claim
was I-Claim
the I-Claim
same I-Claim
in I-Claim
terms I-Claim
of I-Claim
TPV I-Claim
reduction I-Claim
, I-Claim
degarelix B-Claim
showed I-Claim
superiority I-Claim
in I-Claim
LUTS I-Claim
relief I-Claim
in I-Claim
symptomatic I-Claim
patients I-Claim
, I-Claim
which I-Claim
could I-Claim
highlight I-Claim
the I-Claim
different I-Claim
actions I-Claim
of I-Claim
these I-Claim
drugs I-Claim
on I-Claim
extrapituitary I-Claim
gonadotrophin-releasing I-Claim
hormone I-Claim
( I-Claim
GnRH I-Claim
) I-Claim
receptors I-Claim
in I-Claim
the I-Claim
bladder I-Claim
and/or I-Claim
the I-Claim
prostate I-Claim
. I-Claim

The B-Claim
two I-Claim
schedules I-Claim
are I-Claim
equivalent I-Claim
in I-Claim
terms I-Claim
of I-Claim
overall I-Claim
response I-Claim
rate I-Claim
, I-Claim
median I-Claim
time-to-progression I-Claim
and I-Claim
overall I-Claim
survival I-Claim
. I-Claim

Therefore B-Claim
, I-Claim
pemetrexed I-Claim
combined I-Claim
with I-Claim
cisplatin I-Claim
can I-Claim
be I-Claim
used I-Claim
as I-Claim
a I-Claim
safe I-Claim
and I-Claim
effective I-Claim
drug I-Claim
for I-Claim
clinical I-Claim
first-line I-Claim
treatment I-Claim
for I-Claim
previously I-Claim
untreated I-Claim
NSCLC I-Claim
. I-Claim

The B-Claim
analgesic I-Claim
effects I-Claim
of I-Claim
amitriptyline I-Claim
were I-Claim
slight I-Claim
and I-Claim
associated I-Claim
with I-Claim
adverse I-Claim
effects I-Claim
. I-Claim

Patients B-Claim
treated I-Claim
with I-Claim
single-agent I-Claim
E I-Claim
followed I-Claim
by I-Claim
single-agent I-Claim
M I-Claim
had I-Claim
similar I-Claim
survival I-Claim
, I-Claim
but I-Claim
less I-Claim
treatment-related I-Claim
toxicity I-Claim
and I-Claim
better I-Claim
QOL I-Claim
as I-Claim
compared I-Claim
with I-Claim
those I-Claim
treated I-Claim
with I-Claim
CEF I-Claim
followed I-Claim
by I-Claim
MV I-Claim
. I-Claim

Women B-Claim
with I-Claim
breast I-Claim
cancer I-Claim
may I-Claim
have I-Claim
an I-Claim
even I-Claim
higher I-Claim
risk I-Claim
of I-Claim
depression I-Claim
particularly I-Claim
in I-Claim
a I-Claim
postmenopausal I-Claim
or I-Claim
estrogen I-Claim
deficiency I-Claim
state I-Claim
. I-Claim

Erlotinib B-Claim
is I-Claim
highly I-Claim
effective I-Claim
compared I-Claim
with I-Claim
oral I-Claim
vinorelbine I-Claim
in I-Claim
elderly I-Claim
, I-Claim
chemonaive I-Claim
, I-Claim
Taiwanese I-Claim
patients I-Claim
with I-Claim
NSCLC I-Claim
. I-Claim

These B-Claim
findings I-Claim
suggest I-Claim
that I-Claim
ways I-Claim
of I-Claim
making I-Claim
this I-Claim
method I-Claim
of I-Claim
hair I-Claim
removal I-Claim
more I-Claim
widely I-Claim
available I-Claim
to I-Claim
women I-Claim
with I-Claim
facial I-Claim
hirsutism I-Claim
should I-Claim
be I-Claim
considered I-Claim
. I-Claim

There B-Claim
was I-Claim
no I-Claim
significant I-Claim
difference I-Claim
between I-Claim
the I-Claim
two I-Claim
schedules I-Claim
examined I-Claim
in I-Claim
terms I-Claim
of I-Claim
improvement I-Claim
in I-Claim
KP I-Claim
or I-Claim
QOL I-Claim
, I-Claim
but I-Claim
there I-Claim
seemed I-Claim
to I-Claim
be I-Claim
a I-Claim
trend I-Claim
in I-Claim
favor I-Claim
of I-Claim
the I-Claim
3w4 I-Claim
schedule I-Claim
. I-Claim

Future B-Claim
work I-Claim
is I-Claim
needed I-Claim
to I-Claim
improve I-Claim
the I-Claim
design I-Claim
and I-Claim
the I-Claim
planning I-Claim
of I-Claim
these I-Claim
interventions I-Claim
to I-Claim
improve I-Claim
program I-Claim
adherence I-Claim
. I-Claim

In O
this O
trial O
, O
histologic B-Claim
confirmation I-Claim
of I-Claim
N2 I-Claim
disease I-Claim
in I-Claim
the I-Claim
surgical I-Claim
and I-Claim
nonsurgical I-Claim
arms I-Claim
eliminated I-Claim
the I-Claim
usual I-Claim
biases I-Claim
from I-Claim
clinical I-Claim
staging I-Claim
. I-Claim

Systematic B-Claim
assessment I-Claim
of I-Claim
depression I-Claim
is I-Claim
needed I-Claim
in I-Claim
hospice I-Claim
patients I-Claim
. I-Claim

Patient-caregiver B-Claim
dyads I-Claim
benefit I-Claim
when I-Claim
viewed I-Claim
as I-Claim
the I-Claim
'unit I-Claim
of I-Claim
care I-Claim
' I-Claim
. I-Claim

Erlotinib B-Claim
not I-Claim
only I-Claim
improves I-Claim
survival I-Claim
in I-Claim
previously I-Claim
treated I-Claim
patients I-Claim
with I-Claim
NSCLC I-Claim
, I-Claim
but I-Claim
also I-Claim
improves I-Claim
tumor-related I-Claim
symptoms I-Claim
and I-Claim
important I-Claim
aspects I-Claim
of I-Claim
QOL I-Claim
. I-Claim

Standard B-Claim
chemotherapy I-Claim
was I-Claim
superior I-Claim
to I-Claim
capecitabine I-Claim
in I-Claim
improving I-Claim
relapse-free I-Claim
and I-Claim
overall I-Claim
survival I-Claim
for I-Claim
older I-Claim
women I-Claim
with I-Claim
early-stage I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Therefore O
, O
IAD B-Claim
is I-Claim
not I-Claim
a I-Claim
good I-Claim
treatment I-Claim
option I-Claim
for I-Claim
many I-Claim
metastatic I-Claim
prostate I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

A B-Claim
carboplatin I-Claim
containing I-Claim
regimen I-Claim
with I-Claim
better I-Claim
toxicity I-Claim
profile I-Claim
and I-Claim
a I-Claim
similar I-Claim
potentiality I-Claim
for I-Claim
symptoms I-Claim
control I-Claim
offers I-Claim
an I-Claim
option I-Claim
in I-Claim
comparison I-Claim
to I-Claim
similar I-Claim
cisplatin I-Claim
containing I-Claim
combinations I-Claim
in I-Claim
the I-Claim
palliative I-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

Two B-Claim
months I-Claim
after I-Claim
starting I-Claim
treatment I-Claim
there I-Claim
were I-Claim
no I-Claim
significant I-Claim
differences I-Claim
in I-Claim
quality I-Claim
of I-Claim
life I-Claim
between I-Claim
the I-Claim
arms I-Claim
. I-Claim

In B-Claim
vivo I-Claim
data I-Claim
have I-Claim
shown I-Claim
a I-Claim
more I-Claim
potent I-Claim
antiangiogenic I-Claim
effect I-Claim
and I-Claim
a I-Claim
higher I-Claim
antitumor I-Claim
activity I-Claim
of I-Claim
low-dose I-Claim
interferon I-Claim
( I-Claim
IFN I-Claim
) I-Claim
given I-Claim
twice I-Claim
daily I-Claim
. I-Claim

Although B-Claim
these I-Claim
findings I-Claim
are I-Claim
promising I-Claim
, I-Claim
a I-Claim
larger I-Claim
study I-Claim
is I-Claim
needed I-Claim
to I-Claim
determine I-Claim
more I-Claim
specifically I-Claim
what I-Claim
short- I-Claim
and I-Claim
long-term I-Claim
effects I-Claim
are I-Claim
possible I-Claim
. I-Claim

This B-Claim
challenges I-Claim
the I-Claim
current I-Claim
understanding I-Claim
of I-Claim
increasing I-Claim
TMZ I-Claim
dose-intensity I-Claim
by I-Claim
prolonged I-Claim
scheduling I-Claim
. I-Claim

Our B-Claim
preliminary I-Claim
data I-Claim
suggest I-Claim
that I-Claim
rhDNase I-Claim
did I-Claim
not I-Claim
significantly I-Claim
improve I-Claim
study I-Claim
primary I-Claim
endpoints I-Claim
of I-Claim
QOL I-Claim
measures I-Claim
compared I-Claim
with I-Claim
the I-Claim
placebo I-Claim
group I-Claim
. I-Claim

Replacement B-Claim
of I-Claim
most I-Claim
hospital I-Claim
follow-up I-Claim
visits I-Claim
in I-Claim
the I-Claim
first I-Claim
year I-Claim
after I-Claim
breast I-Claim
cancer I-Claim
treatment I-Claim
by I-Claim
nurse-led I-Claim
telephone I-Claim
follow-up I-Claim
does I-Claim
not I-Claim
impede I-Claim
patient I-Claim
outcomes I-Claim
. I-Claim

Erlotinib B-Claim
was I-Claim
effective I-Claim
and I-Claim
well I-Claim
tolerated I-Claim
in I-Claim
Asian I-Claim
patients I-Claim
, I-Claim
producing I-Claim
benefits I-Claim
consistent I-Claim
with I-Claim
those I-Claim
observed I-Claim
in I-Claim
the I-Claim
overall I-Claim
SATURN I-Claim
population I-Claim
. I-Claim

Each B-Claim
of I-Claim
these I-Claim
regimens I-Claim
produced I-Claim
clinically I-Claim
significant I-Claim
responses I-Claim
, I-Claim
and O
the B-Claim
observed I-Claim
median I-Claim
survival I-Claim
( I-Claim
18.9 I-Claim
months I-Claim
for I-Claim
all I-Claim
71 I-Claim
patients I-Claim
) I-Claim
compares I-Claim
favorably I-Claim
with I-Claim
previously I-Claim
published I-Claim
results I-Claim
, I-Claim
especially I-Claim
in I-Claim
the I-Claim
community I-Claim
setting I-Claim
. I-Claim

The B-Claim
-3 I-Claim
and I-Claim
5-year I-Claim
survival I-Claim
rates I-Claim
of I-Claim
nonsurgical I-Claim
therapy I-Claim
were I-Claim
comparable I-Claim
to I-Claim
published I-Claim
surgical I-Claim
trials I-Claim
of I-Claim
N2 I-Claim
disease I-Claim
. I-Claim

DC/CIK B-Claim
treatment I-Claim
had I-Claim
potential I-Claim
benefit I-Claim
for I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non-small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
compared I-Claim
with I-Claim
the I-Claim
control I-Claim
group I-Claim
and I-Claim
had I-Claim
no I-Claim
obvious I-Claim
side I-Claim
effects I-Claim
. I-Claim

In B-Claim
the I-Claim
subset I-Claim
analysis I-Claim
, I-Claim
female I-Claim
patients I-Claim
, I-Claim
those I-Claim
that I-Claim
received I-Claim
high I-Claim
dose I-Claim
irradiation I-Claim
, I-Claim
and I-Claim
those I-Claim
that I-Claim
underwent I-Claim
adjuvant I-Claim
chemotherapy I-Claim
could I-Claim
benefit I-Claim
more I-Claim
from I-Claim
psychosocial I-Claim
intervention I-Claim
. I-Claim

